epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
apitegromab
Apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
atacicept
Atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
Avasopasem
avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Filspari

sparsentan

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Black Box Warnings .

Appropriate Use

available only through restricted distribution program (Filspari REMS) due to risk of hepatotoxicity; prescribers, patients, and pharmacies must enroll at 1-833-513-1325 or www.filsparirems.com

Hepatotoxicity

AST/ALT incr. >3x ULN in up to 3.5% of patients, including cases confirmed with rechallenge; endothelin receptor antagonists have caused elevated AST/ALT, hepatotoxicity, and liver failure; monitor AST/ALT and bilirubin before tx start, then q3mo; interrupt tx and closely monitor if AST/ALT >3x ULN; avoid use if AST/ALT >3x ULN at baseline since monitoring for hepatotoxicity may be more difficult and patients may be at increased risk for serious hepatotoxicity

Embryo-Fetal Toxicity

contraindicated in pregnancy due to risk of fetal harm; obtain negative pregnancy test before tx start; avoid pregnancy by using effective contraception before tx start, during tx, and x2wk after D/C; D/C ASAP if pregnancy detected

Adult Dosing .

Dosage forms:  TAB: 200 mg, 400 mg

Restricted Distribution in US

[1-833-513-1325 or www.filsparirems.com for more info]

IgA nephropathy, primary

[400 mg PO qd]
Start: 200 mg PO qd x14 days; Info: for patients with disease progression risk; see pkg insert for dose adjustments based on AST/ALT; give before meals; consider retitrating from 200 mg PO qd if tx interrupted

renal dosing

[see below]
eGFR >30: no adjustment; eGFR <30: not defined
HD/PD: not defined

hepatic dosing

[see below]
Child-Pugh Class A, B, or C: avoid use

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@2282caa
  • hypersensitivity to drug or ingredient
  • hepatic impairment
  • ALT or AST >3x ULN
  • breastfeeding
  • pregnancy
  • caution: patients of childbearing potential
  • caution: renal impairment, chronic
  • caution: renal artery stenosis
  • caution: CHF, severe
  • caution: volume depletion
  • caution: hypotension risk

Drug Interactions .

Overview

sparsentan

endothelin antagonist; angiotensin II antagonist

Interaction Characteristics:
  • CYP3A4 substrate
  • CYP2B6 inducer, weak
  • CYP2C9 inducer, weak
  • CYP2C19 inducer, weak
  • P-gp inhibitor, weak
  • BCRP inhibitor
  • angiotensin II Type 1 antagonist
  • gastric pH sensitive
  • hyperkalemia
  • hypotensive effects
  • nephrotoxicity

Contraindicated

  • aliskiren
  • Filspari (sparsentan)
    +
    aliskiren
    1 interaction

    Contraindicated

    sparsentan + aliskiren

    contraindicated: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension, including orthostasis, syncope (additive effects)

  • ambrisentan
  • Filspari (sparsentan)
    +
    ambrisentan
    1 interaction

    Contraindicated

    sparsentan + ambrisentan

    contraindicated: combo may incr. risk of hypotension (including orthostasis, syncope), hyperkalemia, nephrotoxicity, other adverse effects (additive effects, duplicate therapy)

  • aprocitentan
  • Filspari (sparsentan)
    +
    aprocitentan
    1 interaction

    Contraindicated

    sparsentan + aprocitentan

    contraindicated: combo may incr. risk of hypotension (including orthostasis, syncope), hyperkalemia, nephrotoxicity, other adverse effects (additive effects, duplicate therapy)

  • atrasentan
  • Filspari (sparsentan)
    +
    atrasentan
    1 interaction

    Contraindicated

    sparsentan + atrasentan

    contraindicated: combo may incr. risk of hypotension (including orthostasis, syncope), hyperkalemia, nephrotoxicity, other adverse effects (additive effects, duplicate therapy)

  • azilsartan medoxomil
  • Filspari (sparsentan)
    +
    azilsartan medoxomil
    1 interaction

    Contraindicated

    sparsentan + azilsartan medoxomil

    contraindicated: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

  • bosentan
  • Filspari (sparsentan)
    +
    bosentan
    1 interaction

    Contraindicated

    sparsentan + bosentan

    contraindicated: combo may incr. risk of hypotension (including orthostasis, syncope), hyperkalemia, nephrotoxicity, other adverse effects (additive effects, duplicate therapy)

  • candesartan cilexetil
  • Filspari (sparsentan)
    +
    candesartan cilexetil
    1 interaction

    Contraindicated

    sparsentan + candesartan cilexetil

    contraindicated: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

  • cidofovir
  • Filspari (sparsentan)
    +
    cidofovir
    1 interaction

    Contraindicated

    sparsentan + cidofovir

    contraindicated; D/C sparsentan at least 7 days prior to cidofovir tx: combo may incr. cidofovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • colchicine
  • Filspari (sparsentan)
    +
    colchicine
    1 interaction

    Contraindicated

    sparsentan + colchicine

    CV RISK REDUCTION: consider monitoring CK, myopathy s/sx; GOUT OR FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, consider decr. colchicine dose during and x14 days after sparsentan use: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (P-gp-mediated transport possibly inhibited)

  • irbesartan
  • Filspari (sparsentan)
    +
    irbesartan
    1 interaction

    Contraindicated

    sparsentan + irbesartan

    contraindicated: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

  • losartan
  • Filspari (sparsentan)
    +
    losartan
    1 interaction

    Contraindicated

    sparsentan + losartan

    contraindicated: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

  • macitentan
  • Filspari (sparsentan)
    +
    macitentan
    1 interaction

    Contraindicated

    sparsentan + macitentan

    contraindicated: combo may incr. risk of hypotension (including orthostasis, syncope), hyperkalemia, nephrotoxicity, other adverse effects (additive effects, duplicate therapy)

  • olmesartan medoxomil
  • Filspari (sparsentan)
    +
    olmesartan medoxomil
    1 interaction

    Contraindicated

    sparsentan + olmesartan medoxomil

    contraindicated: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

  • sparsentan
  • Filspari (sparsentan)
    +
    sparsentan
    1 interaction

    Contraindicated

    sparsentan + sparsentan

    contraindicated: combo may incr. risk of hypotension (including orthostasis, syncope), hyperkalemia, nephrotoxicity, other adverse effects (additive effects, duplicate therapy)

  • telmisartan
  • Filspari (sparsentan)
    +
    telmisartan
    1 interaction

    Contraindicated

    sparsentan + telmisartan

    contraindicated: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

  • valsartan
  • Filspari (sparsentan)
    +
    valsartan
    1 interaction

    Contraindicated

    sparsentan + valsartan

    contraindicated: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

Avoid/Use Alternative

  • adagrasib
  • Filspari (sparsentan)
    +
    adagrasib
    1 interaction

    Avoid/Use Alternative

    sparsentan + adagrasib

    avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • aldesleukin
  • Filspari (sparsentan)
    +
    aldesleukin
    1 interaction

    Avoid/Use Alternative

    sparsentan + aldesleukin

    avoid combo: combo may incr. risk of nephrotoxicity, severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

  • alpelisib
  • Filspari (sparsentan)
    +
    alpelisib
    1 interaction

    Avoid/Use Alternative

    sparsentan + alpelisib

    use alternative: combo may incr. alpelisib levels, risk of adverse effects (BCRP-mediated transport possibly inhibited)

  • amikacin
  • Filspari (sparsentan)
    +
    amikacin
    1 interaction

    Avoid/Use Alternative

    sparsentan + amikacin

    use alternative or monitor amikacin levels, renal fxn, ototoxicity: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • amikacin inhaled
  • Filspari (sparsentan)
    +
    amikacin inhaled
    1 interaction

    Avoid/Use Alternative

    sparsentan + amikacin inhaled

    use alternative or monitor renal fxn, ototoxicity: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • amiloride
  • Filspari (sparsentan)
    +
    amiloride
    1 interaction

    Avoid/Use Alternative

    sparsentan + amiloride

    if hypokalemia use, monitor potassium, renal fxn, BP; otherwise, avoid combo: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension, including orthostasis, syncope (additive effects)

  • angiotensin II
  • Filspari (sparsentan)
    +
    angiotensin II
    1 interaction

    Avoid/Use Alternative

    sparsentan + angiotensin II

    use alternative or monitor BP: combo may decr. angiotensin II efficacy (antagonistic effects)

  • apalutamide
  • Filspari (sparsentan)
    +
    apalutamide
    1 interaction

    Avoid/Use Alternative

    sparsentan + apalutamide

    avoid combo: combo may decr. sparsentan levels, efficacy (hepatic metabolism induced)

  • apixaban
  • Filspari (sparsentan)
    +
    apixaban
    1 interaction

    Avoid/Use Alternative

    sparsentan + apixaban

    ADULT PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban 5mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

  • atazanavir
  • Filspari (sparsentan)
    +
    atazanavir
    1 interaction

    Avoid/Use Alternative

    sparsentan + atazanavir

    avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • benazepril
  • Filspari (sparsentan)
    +
    benazepril
    1 interaction

    Avoid/Use Alternative

    sparsentan + benazepril

    use alternative or monitor BP, renal fxn, potassium: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension, including orthostasis, syncope (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • bumetanide
  • Filspari (sparsentan)
    +
    bumetanide
    1 interaction

    Avoid/Use Alternative

    sparsentan + bumetanide

    use alternative or monitor BP, renal fxn: combo may incr. risk of nephrotoxicity, hypotension, including orthostasis, syncope (additive effects)

  • butalbital
  • Filspari (sparsentan)
    +
    butalbital
    1 interaction

    Avoid/Use Alternative

    sparsentan + butalbital

    avoid combo: combo may decr. sparsentan levels, efficacy (hepatic metabolism induced)

  • captopril
  • Filspari (sparsentan)
    +
    captopril
    1 interaction

    Avoid/Use Alternative

    sparsentan + captopril

    use alternative or monitor BP, renal fxn, potassium: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension, including orthostasis, syncope (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • carbamazepine
  • Filspari (sparsentan)
    +
    carbamazepine
    1 interaction

    Avoid/Use Alternative

    sparsentan + carbamazepine

    avoid combo: combo may decr. sparsentan levels, efficacy (hepatic metabolism induced)

  • ceritinib
  • Filspari (sparsentan)
    +
    ceritinib
    1 interaction

    Avoid/Use Alternative

    sparsentan + ceritinib

    avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • chloramphenicol
  • Filspari (sparsentan)
    +
    chloramphenicol
    1 interaction

    Avoid/Use Alternative

    sparsentan + chloramphenicol

    avoid combo or hold sparsentan during chloramphenicol use: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • cimetidine
  • Filspari (sparsentan)
    +
    cimetidine
    1 interaction

    Avoid/Use Alternative

    sparsentan + cimetidine

    avoid combo: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • cladribine oral
  • Filspari (sparsentan)
    +
    cladribine oral
    1 interaction

    Avoid/Use Alternative

    sparsentan + cladribine oral

    use alternative or monitor CBC: combo may incr. cladribine levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated transport possibly inhibited)

  • clarithromycin
  • Filspari (sparsentan)
    +
    clarithromycin
    1 interaction

    Avoid/Use Alternative

    sparsentan + clarithromycin

    avoid combo or hold sparsentan during clarithromycin use: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • clofarabine
  • Filspari (sparsentan)
    +
    clofarabine
    1 interaction

    Avoid/Use Alternative

    sparsentan + clofarabine

    monitor CBC, renal fxn, BP; avoid sparsentan during 5 day clofarabine tx: combo may incr. clofarabine levels, risk of serious infection, myelosuppression, nephrotoxicity, severe hypotension (including orthostasis, syncope), other adverse effects (additive effects)

  • cobicistat
  • Filspari (sparsentan)
    +
    cobicistat
    1 interaction

    Avoid/Use Alternative

    sparsentan + cobicistat

    avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • dabigatran
  • Filspari (sparsentan)
    +
    dabigatran
    1 interaction

    Avoid/Use Alternative

    sparsentan + dabigatran

    ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (including life-threatening), other adverse effects (P-gp-mediated transport possibly inhibited)

  • dexlansoprazole
  • Filspari (sparsentan)
    +
    dexlansoprazole
    1 interaction

    Avoid/Use Alternative

    sparsentan + dexlansoprazole

    avoid combo: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • enalapril
  • Filspari (sparsentan)
    +
    enalapril
    1 interaction

    Avoid/Use Alternative

    sparsentan + enalapril

    use alternative or monitor BP, renal fxn, potassium: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension, including orthostasis, syncope (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • enalaprilat
  • Filspari (sparsentan)
    +
    enalaprilat
    1 interaction

    Avoid/Use Alternative

    sparsentan + enalaprilat

    use alternative or monitor BP, renal fxn, potassium: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension, including orthostasis, syncope (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • encorafenib
  • Filspari (sparsentan)
    +
    encorafenib
    1 interaction

    Avoid/Use Alternative

    sparsentan + encorafenib

    avoid combo: combo may decr. sparsentan levels, efficacy (hepatic metabolism induced)

  • ensartinib
  • Filspari (sparsentan)
    +
    ensartinib
    1 interaction

    Avoid/Use Alternative

    sparsentan + ensartinib

    avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (P-gp-mediated transport possibly inhibited)

  • enzalutamide
  • Filspari (sparsentan)
    +
    enzalutamide
    1 interaction

    Avoid/Use Alternative

    sparsentan + enzalutamide

    avoid combo: combo may decr. sparsentan levels, efficacy (hepatic metabolism induced)

  • esomeprazole
  • Filspari (sparsentan)
    +
    esomeprazole
    1 interaction

    Avoid/Use Alternative

    sparsentan + esomeprazole

    avoid combo: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • estradiol (contraceptive)
  • Filspari (sparsentan)
    +
    estradiol (contraceptive)
    1 interaction

    Avoid/Use Alternative

    sparsentan + estradiol (contraceptive)

    use additional non-hormonal or alternative contraception during and x28 days after sparsentan tx: combo may decr. estradiol levels, contraceptive efficacy (hepatic metabolism induced)

  • ethinyl estradiol (contraceptive)
  • Filspari (sparsentan)
    +
    ethinyl estradiol (contraceptive)
    1 interaction

    Avoid/Use Alternative

    sparsentan + ethinyl estradiol (contraceptive)

    use additional non-hormonal or alternative contraception during and x28 days after sparsentan tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

  • famotidine
  • Filspari (sparsentan)
    +
    famotidine
    1 interaction

    Avoid/Use Alternative

    sparsentan + famotidine

    avoid combo: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • foscarnet
  • Filspari (sparsentan)
    +
    foscarnet
    1 interaction

    Avoid/Use Alternative

    sparsentan + foscarnet

    use alternative or monitor CBC, renal fxn: combo may incr. foscarnet levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • fosinopril
  • Filspari (sparsentan)
    +
    fosinopril
    1 interaction

    Avoid/Use Alternative

    sparsentan + fosinopril

    use alternative or monitor BP, renal fxn, potassium: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension, including orthostasis, syncope (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • fosphenytoin
  • Filspari (sparsentan)
    +
    fosphenytoin
    1 interaction

    Avoid/Use Alternative

    sparsentan + fosphenytoin

    avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

  • ganciclovir
  • Filspari (sparsentan)
    +
    ganciclovir
    1 interaction

    Avoid/Use Alternative

    sparsentan + ganciclovir

    use alternative or monitor CBC, renal fxn: combo may incr. ganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • gentamicin
  • Filspari (sparsentan)
    +
    gentamicin
    1 interaction

    Avoid/Use Alternative

    sparsentan + gentamicin

    use alternative or monitor gentamicin levels, renal fxn, ototoxicity: combo may incr. gentamicin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • idelalisib
  • Filspari (sparsentan)
    +
    idelalisib
    1 interaction

    Avoid/Use Alternative

    sparsentan + idelalisib

    avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • itraconazole
  • Filspari (sparsentan)
    +
    itraconazole
    1 interaction

    Avoid/Use Alternative

    sparsentan + itraconazole

    avoid combo or hold sparsentan during and x2wk after itraconazole tx: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • ivosidenib
  • Filspari (sparsentan)
    +
    ivosidenib
    1 interaction

    Avoid/Use Alternative

    sparsentan + ivosidenib

    avoid combo: combo may decr. sparsentan levels, efficacy (hepatic metabolism induced)

  • ketoconazole
  • Filspari (sparsentan)
    +
    ketoconazole
    1 interaction

    Avoid/Use Alternative

    sparsentan + ketoconazole

    avoid combo or hold sparsentan during and up to 1wk after ketoconazole tx: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • lansoprazole
  • Filspari (sparsentan)
    +
    lansoprazole
    1 interaction

    Avoid/Use Alternative

    sparsentan + lansoprazole

    avoid combo: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • levoketoconazole
  • Filspari (sparsentan)
    +
    levoketoconazole
    1 interaction

    Avoid/Use Alternative

    sparsentan + levoketoconazole

    avoid combo or hold sparsentan during levoketoconazole use: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • lisinopril
  • Filspari (sparsentan)
    +
    lisinopril
    1 interaction

    Avoid/Use Alternative

    sparsentan + lisinopril

    use alternative or monitor BP, renal fxn, potassium: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension, including orthostasis, syncope (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • lofexidine
  • Filspari (sparsentan)
    +
    lofexidine
    1 interaction

    Avoid/Use Alternative

    sparsentan + lofexidine

    use alternative or monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • lonafarnib
  • Filspari (sparsentan)
    +
    lonafarnib
    1 interaction

    Avoid/Use Alternative

    sparsentan + lonafarnib

    avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • lopinavir/ritonavir
  • Filspari (sparsentan)
    +
    lopinavir/ ritonavir
    1 interaction

    Avoid/Use Alternative

    sparsentan + lopinavir/ ritonavir

    avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • lumacaftor/ivacaftor
  • Filspari (sparsentan)
    +
    lumacaftor/ ivacaftor
    1 interaction

    Avoid/Use Alternative

    sparsentan + lumacaftor/ ivacaftor

    avoid combo: combo may decr. sparsentan levels, efficacy (hepatic metabolism induced)

  • mannitol
  • Filspari (sparsentan)
    +
    mannitol
    1 interaction

    Avoid/Use Alternative

    sparsentan + mannitol

    use alternative or monitor renal fxn: combo may incr. mannitol levels, risk of nephrotoxicity, neurotoxicity (including life-threatening), other adverse effects (additive effects)

  • mavacamten
  • Filspari (sparsentan)
    +
    mavacamten
    1 interaction

    Avoid/Use Alternative

    sparsentan + mavacamten

    consider alternative or monitor cardiac fxn: combo may decr. mavacamten levels, efficacy (hepatic metabolism possibly induced)

  • meperidine
  • Filspari (sparsentan)
    +
    meperidine
    1 interaction

    Avoid/Use Alternative

    sparsentan + meperidine

    use alternative or monitor withdrawal sx, BP: combo may decr. meperidine levels, efficacy; may incr. normeperidine levels, risk of neurotoxicity, severe hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism induced, incr. toxic metabolite formation; additive effects)

  • methotrexate
  • Filspari (sparsentan)
    +
    methotrexate
    1 interaction

    Avoid/Use Alternative

    sparsentan + methotrexate

    use alternative or monitor CBC, renal fxn: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (BCRP-mediated transport possibly inhibited, additive effects)

  • mifepristone
  • Filspari (sparsentan)
    +
    mifepristone
    1 interaction

    Avoid/Use Alternative

    sparsentan + mifepristone

    avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • mitotane
  • Filspari (sparsentan)
    +
    mitotane
    1 interaction

    Avoid/Use Alternative

    sparsentan + mitotane

    avoid combo: combo may decr. sparsentan levels, efficacy (hepatic metabolism induced)

  • moexipril
  • Filspari (sparsentan)
    +
    moexipril
    1 interaction

    Avoid/Use Alternative

    sparsentan + moexipril

    use alternative or monitor BP, renal fxn, potassium: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension, including orthostasis, syncope (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • nefazodone
  • Filspari (sparsentan)
    +
    nefazodone
    1 interaction

    Avoid/Use Alternative

    sparsentan + nefazodone

    avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • nelfinavir
  • Filspari (sparsentan)
    +
    nelfinavir
    1 interaction

    Avoid/Use Alternative

    sparsentan + nelfinavir

    avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects; may decr. nelfinavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • neratinib
  • Filspari (sparsentan)
    +
    neratinib
    1 interaction

    Avoid/Use Alternative

    sparsentan + neratinib

    avoid combo if also combined w/ mod-strong CYP3A4 inhibitor; otherwise, caution advised: combo may incr. neratinib levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

  • nizatidine
  • Filspari (sparsentan)
    +
    nizatidine
    1 interaction

    Avoid/Use Alternative

    sparsentan + nizatidine

    avoid combo: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • norgestimate (contraceptive)
  • Filspari (sparsentan)
    +
    norgestimate (contraceptive)
    1 interaction

    Avoid/Use Alternative

    sparsentan + norgestimate (contraceptive)

    use additional non-hormonal or alternative contraception during and x28 days after sparsentan tx: combo may decr. norgestimate and active metabolites levels, contraceptive efficacy (hepatic metabolism induced)

  • omeprazole
  • Filspari (sparsentan)
    +
    omeprazole
    1 interaction

    Avoid/Use Alternative

    sparsentan + omeprazole

    avoid combo: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • oxaliplatin
  • Filspari (sparsentan)
    +
    oxaliplatin
    1 interaction

    Avoid/Use Alternative

    sparsentan + oxaliplatin

    use alternative or monitor ECG, CBC, renal fxn, ototoxicity: combo may incr. oxaliplatin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • pantoprazole
  • Filspari (sparsentan)
    +
    pantoprazole
    1 interaction

    Avoid/Use Alternative

    sparsentan + pantoprazole

    avoid combo: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • pazopanib
  • Filspari (sparsentan)
    +
    pazopanib
    1 interaction

    Avoid/Use Alternative

    sparsentan + pazopanib

    avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (BCRP-mediated transport possibly inhibited, additive effects)

  • pentamidine
  • Filspari (sparsentan)
    +
    pentamidine
    1 interaction

    Avoid/Use Alternative

    sparsentan + pentamidine

    use alternative or monitor renal fxn, BP: combo may incr. risk of nephrotoxicity, severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

  • pentobarbital
  • Filspari (sparsentan)
    +
    pentobarbital
    1 interaction

    Avoid/Use Alternative

    sparsentan + pentobarbital

    avoid combo: combo may decr. sparsentan levels, efficacy; may incr. risk of hypotension, including orthostasis, syncope (hepatic metabolism induced; additive effects)

  • perindopril
  • Filspari (sparsentan)
    +
    perindopril
    1 interaction

    Avoid/Use Alternative

    sparsentan + perindopril

    use alternative or monitor BP, renal fxn, potassium: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension, including orthostasis, syncope (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • phenobarbital
  • Filspari (sparsentan)
    +
    phenobarbital
    1 interaction

    Avoid/Use Alternative

    sparsentan + phenobarbital

    avoid combo: combo may decr. sparsentan levels, efficacy; may incr. risk of hypotension, including orthostasis, syncope (hepatic metabolism induced; additive effects)

  • phenytoin
  • Filspari (sparsentan)
    +
    phenytoin
    1 interaction

    Avoid/Use Alternative

    sparsentan + phenytoin

    avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

  • polymyxin B
  • Filspari (sparsentan)
    +
    polymyxin B
    1 interaction

    Avoid/Use Alternative

    sparsentan + polymyxin B

    avoid combo: combo may incr. risk of nephrotoxicity (additive effects)

  • posaconazole
  • Filspari (sparsentan)
    +
    posaconazole
    1 interaction

    Avoid/Use Alternative

    sparsentan + posaconazole

    avoid combo or hold sparsentan during posaconazole use: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • potassium chloride
  • Filspari (sparsentan)
    +
    potassium chloride
    1 interaction

    Avoid/Use Alternative

    sparsentan + potassium chloride

    IV potassium chloride: use alternative or monitor potassium, ECG; ORAL potassium: monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

  • potassium phosphate
  • Filspari (sparsentan)
    +
    potassium phosphate
    1 interaction

    Avoid/Use Alternative

    sparsentan + potassium phosphate

    use alternative or monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

  • pralsetinib
  • Filspari (sparsentan)
    +
    pralsetinib
    1 interaction

    Avoid/Use Alternative

    sparsentan + pralsetinib

    use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 400 mg qd and also combined w/ strong CYP3A4 inhibitor: decr. to 200 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport possibly inhibited)

  • primidone
  • Filspari (sparsentan)
    +
    primidone
    1 interaction

    Avoid/Use Alternative

    sparsentan + primidone

    avoid combo: combo may decr. sparsentan levels, efficacy (hepatic metabolism induced)

  • quinapril
  • Filspari (sparsentan)
    +
    quinapril
    1 interaction

    Avoid/Use Alternative

    sparsentan + quinapril

    use alternative or monitor BP, renal fxn, potassium: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension, including orthostasis, syncope (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • rabeprazole
  • Filspari (sparsentan)
    +
    rabeprazole
    1 interaction

    Avoid/Use Alternative

    sparsentan + rabeprazole

    avoid combo: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • ramipril
  • Filspari (sparsentan)
    +
    ramipril
    1 interaction

    Avoid/Use Alternative

    sparsentan + ramipril

    use alternative or monitor BP, renal fxn, potassium: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension, including orthostasis, syncope (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • relugolix
  • Filspari (sparsentan)
    +
    relugolix
    1 interaction

    Avoid/Use Alternative

    sparsentan + relugolix

    PROSTATE CANCER: may hold relugolix if sparsentan tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before sparsentan; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before sparsentan: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

  • repotrectinib
  • Filspari (sparsentan)
    +
    repotrectinib
    1 interaction

    Avoid/Use Alternative

    sparsentan + repotrectinib

    avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

  • ribociclib
  • Filspari (sparsentan)
    +
    ribociclib
    1 interaction

    Avoid/Use Alternative

    sparsentan + ribociclib

    avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • rifabutin
  • Filspari (sparsentan)
    +
    rifabutin
    1 interaction

    Avoid/Use Alternative

    sparsentan + rifabutin

    avoid combo: combo may decr. sparsentan levels, efficacy (hepatic metabolism induced)

  • rifampin
  • Filspari (sparsentan)
    +
    rifampin
    1 interaction

    Avoid/Use Alternative

    sparsentan + rifampin

    avoid combo: combo may decr. sparsentan levels, efficacy (hepatic metabolism induced)

  • ritonavir
  • Filspari (sparsentan)
    +
    ritonavir
    1 interaction

    Avoid/Use Alternative

    sparsentan + ritonavir

    avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • rivaroxaban
  • Filspari (sparsentan)
    +
    rivaroxaban
    1 interaction

    Avoid/Use Alternative

    sparsentan + rivaroxaban

    avoid combo if also combined w/ strong CYP3A4 inhibitor; use alternative if CrCl <80 and combined w/ moderate CYP3A4 inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (BCRP-mediated transport possibly inhibited, P-gp-mediated transport possibly inhibited)

  • sirolimus albumin-bound
  • Filspari (sparsentan)
    +
    sirolimus albumin-bound
    1 interaction

    Avoid/Use Alternative

    sparsentan + sirolimus albumin-bound

    avoid combo: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects (P-gp-mediated transport possibly inhibited)

  • St. John's wort
  • Filspari (sparsentan)
    +
    St. John's wort
    1 interaction

    Avoid/Use Alternative

    sparsentan + St. John's wort

    avoid combo: combo may decr. sparsentan levels, efficacy (hepatic metabolism induced)

  • streptomycin
  • Filspari (sparsentan)
    +
    streptomycin
    1 interaction

    Avoid/Use Alternative

    sparsentan + streptomycin

    use alternative or monitor renal fxn, ototoxicity: combo may incr. streptomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • streptozocin
  • Filspari (sparsentan)
    +
    streptozocin
    1 interaction

    Avoid/Use Alternative

    sparsentan + streptozocin

    use alternative or monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • tacrolimus
  • Filspari (sparsentan)
    +
    tacrolimus
    1 interaction

    Avoid/Use Alternative

    sparsentan + tacrolimus

    consider alternative or monitor tacrolimus levels, ECG, renal fxn, potassium: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, hyperkalemia, other adverse effects (P-gp-mediated transport possibly inhibited, additive effects)

  • tenofovir disoproxil
  • Filspari (sparsentan)
    +
    tenofovir disoproxil
    1 interaction

    Avoid/Use Alternative

    sparsentan + tenofovir disoproxil

    use alternative or monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport possibly inhibited, gut BCRP-mediated transport possibly inhibited, additive effects)

  • tipranavir
  • Filspari (sparsentan)
    +
    tipranavir
    1 interaction

    Avoid/Use Alternative

    sparsentan + tipranavir

    avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • tobramycin
  • Filspari (sparsentan)
    +
    tobramycin
    1 interaction

    Avoid/Use Alternative

    sparsentan + tobramycin

    use alternative or monitor tobramycin levels, renal fxn, ototoxicity: combo may incr. tobramycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • tobramycin inhaled
  • Filspari (sparsentan)
    +
    tobramycin inhaled
    1 interaction

    Avoid/Use Alternative

    sparsentan + tobramycin inhaled

    use alternative or monitor renal fxn, ototoxicity: combo may incr. tobramycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • topotecan
  • Filspari (sparsentan)
    +
    topotecan
    1 interaction

    Avoid/Use Alternative

    sparsentan + topotecan

    avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut P-gp-mediated transport possibly inhibited; gut BCRP-mediated transport possibly inhibited)

  • trandolapril
  • Filspari (sparsentan)
    +
    trandolapril
    1 interaction

    Avoid/Use Alternative

    sparsentan + trandolapril

    use alternative or monitor BP, renal fxn, potassium: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension, including orthostasis, syncope (additive effects, dual blockade of renin-angiotensin-aldosterone system)

  • tucatinib
  • Filspari (sparsentan)
    +
    tucatinib
    1 interaction

    Avoid/Use Alternative

    sparsentan + tucatinib

    avoid combo: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • valganciclovir
  • Filspari (sparsentan)
    +
    valganciclovir
    1 interaction

    Avoid/Use Alternative

    sparsentan + valganciclovir

    use alternative or monitor CBC, renal fxn: combo may incr. ganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • venetoclax
  • Filspari (sparsentan)
    +
    venetoclax
    1 interaction

    Avoid/Use Alternative

    sparsentan + venetoclax

    monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport possibly inhibited)

  • vonoprazan
  • Filspari (sparsentan)
    +
    vonoprazan
    1 interaction

    Avoid/Use Alternative

    sparsentan + vonoprazan

    avoid combo: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • voriconazole
  • Filspari (sparsentan)
    +
    voriconazole
    1 interaction

    Avoid/Use Alternative

    sparsentan + voriconazole

    avoid combo or hold sparsentan during voriconazole use: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects; may decr. voriconazole levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

Monitor/Modify Tx

  • acebutolol
  • Filspari (sparsentan)
    +
    acebutolol
    1 interaction

    Monitor/Modify Tx

    sparsentan + acebutolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • acyclovir
  • Filspari (sparsentan)
    +
    acyclovir
    1 interaction

    Monitor/Modify Tx

    sparsentan + acyclovir

    monitor renal fxn: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • adefovir dipivoxil
  • Filspari (sparsentan)
    +
    adefovir dipivoxil
    1 interaction

    Monitor/Modify Tx

    sparsentan + adefovir dipivoxil

    monitor renal fxn: combo may incr. adefovir levels, risk of nephrotoxicity, other adverse effects (renal excretion decreased by nephrotoxic agents, additive effects)

  • afatinib
  • Filspari (sparsentan)
    +
    afatinib
    1 interaction

    Monitor/Modify Tx

    sparsentan + afatinib

    decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

  • alectinib
  • Filspari (sparsentan)
    +
    alectinib
    1 interaction

    Monitor/Modify Tx

    sparsentan + alectinib

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • alfentanil
  • Filspari (sparsentan)
    +
    alfentanil
    1 interaction

    Monitor/Modify Tx

    sparsentan + alfentanil

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • alfuzosin
  • Filspari (sparsentan)
    +
    alfuzosin
    1 interaction

    Monitor/Modify Tx

    sparsentan + alfuzosin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • allopurinol
  • Filspari (sparsentan)
    +
    allopurinol
    1 interaction

    Monitor/Modify Tx

    sparsentan + allopurinol

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • alprostadil intracavernous
  • Filspari (sparsentan)
    +
    alprostadil intracavernous
    1 interaction

    Monitor/Modify Tx

    sparsentan + alprostadil intracavernous

    monitor BP: combo may increase risk of hypotension, including orthostasis, syncope (additive effects)

  • aluminum hydroxide
  • Filspari (sparsentan)
    +
    aluminum hydroxide
    1 interaction

    Monitor/Modify Tx

    sparsentan + aluminum hydroxide

    separate admin. by at least 2h: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • amantadine
  • Filspari (sparsentan)
    +
    amantadine
    1 interaction

    Monitor/Modify Tx

    sparsentan + amantadine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • amifostine
  • Filspari (sparsentan)
    +
    amifostine
    1 interaction

    Monitor/Modify Tx

    sparsentan + amifostine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • amitriptyline
  • Filspari (sparsentan)
    +
    amitriptyline
    1 interaction

    Monitor/Modify Tx

    sparsentan + amitriptyline

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • amlodipine
  • Filspari (sparsentan)
    +
    amlodipine
    1 interaction

    Monitor/Modify Tx

    sparsentan + amlodipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • amoxapine
  • Filspari (sparsentan)
    +
    amoxapine
    1 interaction

    Monitor/Modify Tx

    sparsentan + amoxapine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • amphotericin
  • Filspari (sparsentan)
    +
    amphotericin
    1 interaction

    Monitor/Modify Tx

    sparsentan + amphotericin

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • anthrax immune globulin
  • Filspari (sparsentan)
    +
    anthrax immune globulin
    1 interaction

    Monitor/Modify Tx

    sparsentan + anthrax immune globulin

    monitor renal fxn; use lowest anthrax immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • apomorphine
  • Filspari (sparsentan)
    +
    apomorphine
    1 interaction

    Monitor/Modify Tx

    sparsentan + apomorphine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • apraclonidine ophthalmic
  • Filspari (sparsentan)
    +
    apraclonidine ophthalmic
    1 interaction

    Monitor/Modify Tx

    sparsentan + apraclonidine ophthalmic

    monitor BP if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • aprepitant
  • Filspari (sparsentan)
    +
    aprepitant
    1 interaction

    Monitor/Modify Tx

    sparsentan + aprepitant

    if aprepitant 3-day regimen, monitor BP, potassium, renal fxn; aprepitant single dose-regimen OK: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • aripiprazole bimonthly injection
  • Filspari (sparsentan)
    +
    aripiprazole bimonthly injection
    1 interaction

    Monitor/Modify Tx

    sparsentan + aripiprazole bimonthly injection

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • aripiprazole lauroxil
  • Filspari (sparsentan)
    +
    aripiprazole lauroxil
    1 interaction

    Monitor/Modify Tx

    sparsentan + aripiprazole lauroxil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • aripiprazole monthly injection
  • Filspari (sparsentan)
    +
    aripiprazole monthly injection
    1 interaction

    Monitor/Modify Tx

    sparsentan + aripiprazole monthly injection

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • aripiprazole oral
  • Filspari (sparsentan)
    +
    aripiprazole oral
    1 interaction

    Monitor/Modify Tx

    sparsentan + aripiprazole oral

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • articaine
  • Filspari (sparsentan)
    +
    articaine
    1 interaction

    Monitor/Modify Tx

    sparsentan + articaine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • asenapine
  • Filspari (sparsentan)
    +
    asenapine
    1 interaction

    Monitor/Modify Tx

    sparsentan + asenapine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • aspirin
  • Filspari (sparsentan)
    +
    aspirin
    1 interaction

    Monitor/Modify Tx

    sparsentan + aspirin

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • atenolol
  • Filspari (sparsentan)
    +
    atenolol
    1 interaction

    Monitor/Modify Tx

    sparsentan + atenolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • atorvastatin
  • Filspari (sparsentan)
    +
    atorvastatin
    1 interaction

    Monitor/Modify Tx

    sparsentan + atorvastatin

    monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport possibly inhibited, P-gp-mediated transport possibly inhibited)

  • auranofin
  • Filspari (sparsentan)
    +
    auranofin
    1 interaction

    Monitor/Modify Tx

    sparsentan + auranofin

    monitor renal fxn: combo may incr. auranofin levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • avacopan
  • Filspari (sparsentan)
    +
    avacopan
    1 interaction

    Monitor/Modify Tx

    sparsentan + avacopan

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • avanafil
  • Filspari (sparsentan)
    +
    avanafil
    1 interaction

    Monitor/Modify Tx

    sparsentan + avanafil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • axitinib
  • Filspari (sparsentan)
    +
    axitinib
    1 interaction

    Monitor/Modify Tx

    sparsentan + axitinib

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • balsalazide
  • Filspari (sparsentan)
    +
    balsalazide
    1 interaction

    Monitor/Modify Tx

    sparsentan + balsalazide

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • berberine
  • Filspari (sparsentan)
    +
    berberine
    1 interaction

    Monitor/Modify Tx

    sparsentan + berberine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • berotralstat
  • Filspari (sparsentan)
    +
    berotralstat
    1 interaction

    Monitor/Modify Tx

    sparsentan + berotralstat

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • betaxolol
  • Filspari (sparsentan)
    +
    betaxolol
    1 interaction

    Monitor/Modify Tx

    sparsentan + betaxolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • betaxolol ophthalmic
  • Filspari (sparsentan)
    +
    betaxolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    sparsentan + betaxolol ophthalmic

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • bethanechol
  • Filspari (sparsentan)
    +
    bethanechol
    1 interaction

    Monitor/Modify Tx

    sparsentan + bethanechol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • bevacizumab
  • Filspari (sparsentan)
    +
    bevacizumab
    1 interaction

    Monitor/Modify Tx

    sparsentan + bevacizumab

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • bexagliflozin
  • Filspari (sparsentan)
    +
    bexagliflozin
    1 interaction

    Monitor/Modify Tx

    sparsentan + bexagliflozin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • bisoprolol
  • Filspari (sparsentan)
    +
    bisoprolol
    1 interaction

    Monitor/Modify Tx

    sparsentan + bisoprolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • bleomycin
  • Filspari (sparsentan)
    +
    bleomycin
    1 interaction

    Monitor/Modify Tx

    sparsentan + bleomycin

    monitor renal fxn; decr. bleomycin dose based on CrCl: combo may incr. bleomycin levels, risk of pulmonary toxicities (including life-threatening), other adverse effects (renal excretion decreased)

  • bortezomib
  • Filspari (sparsentan)
    +
    bortezomib
    1 interaction

    Monitor/Modify Tx

    sparsentan + bortezomib

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • botulism immune globulin
  • Filspari (sparsentan)
    +
    botulism immune globulin
    1 interaction

    Monitor/Modify Tx

    sparsentan + botulism immune globulin

    monitor renal fxn; use lowest botulism immune globulin concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • brexpiprazole
  • Filspari (sparsentan)
    +
    brexpiprazole
    1 interaction

    Monitor/Modify Tx

    sparsentan + brexpiprazole

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • brimonidine ophthalmic
  • Filspari (sparsentan)
    +
    brimonidine ophthalmic
    1 interaction

    Monitor/Modify Tx

    sparsentan + brimonidine ophthalmic

    monitor BP if elevated IOP or presbyopia use; OTC ocular redness use OK: combo may increase risk of hypotension, including orthostasis, syncope (additive effects)

  • brimonidine topical
  • Filspari (sparsentan)
    +
    brimonidine topical
    1 interaction

    Monitor/Modify Tx

    sparsentan + brimonidine topical

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • bromocriptine
  • Filspari (sparsentan)
    +
    bromocriptine
    1 interaction

    Monitor/Modify Tx

    sparsentan + bromocriptine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • bupivacaine
  • Filspari (sparsentan)
    +
    bupivacaine
    1 interaction

    Monitor/Modify Tx

    sparsentan + bupivacaine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • bupivacaine liposomal
  • Filspari (sparsentan)
    +
    bupivacaine liposomal
    1 interaction

    Monitor/Modify Tx

    sparsentan + bupivacaine liposomal

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • buprenorphine
  • Filspari (sparsentan)
    +
    buprenorphine
    1 interaction

    Monitor/Modify Tx

    sparsentan + buprenorphine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • butorphanol
  • Filspari (sparsentan)
    +
    butorphanol
    1 interaction

    Monitor/Modify Tx

    sparsentan + butorphanol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • cabergoline
  • Filspari (sparsentan)
    +
    cabergoline
    1 interaction

    Monitor/Modify Tx

    sparsentan + cabergoline

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • cabozantinib
  • Filspari (sparsentan)
    +
    cabozantinib
    1 interaction

    Monitor/Modify Tx

    sparsentan + cabozantinib

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • calcium carbonate
  • Filspari (sparsentan)
    +
    calcium carbonate
    1 interaction

    Monitor/Modify Tx

    sparsentan + calcium carbonate

    separate admin. by at least 2h: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • canagliflozin
  • Filspari (sparsentan)
    +
    canagliflozin
    1 interaction

    Monitor/Modify Tx

    sparsentan + canagliflozin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • cannabis
  • Filspari (sparsentan)
    +
    cannabis
    1 interaction

    Monitor/Modify Tx

    sparsentan + cannabis

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • capecitabine
  • Filspari (sparsentan)
    +
    capecitabine
    1 interaction

    Monitor/Modify Tx

    sparsentan + capecitabine

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • carboplatin
  • Filspari (sparsentan)
    +
    carboplatin
    1 interaction

    Monitor/Modify Tx

    sparsentan + carboplatin

    monitor CBC, renal fxn, ototoxicity: combo may incr. carboplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • carfilzomib
  • Filspari (sparsentan)
    +
    carfilzomib
    1 interaction

    Monitor/Modify Tx

    sparsentan + carfilzomib

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • cariprazine
  • Filspari (sparsentan)
    +
    cariprazine
    1 interaction

    Monitor/Modify Tx

    sparsentan + cariprazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • carteolol ophthalmic
  • Filspari (sparsentan)
    +
    carteolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    sparsentan + carteolol ophthalmic

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • carvedilol
  • Filspari (sparsentan)
    +
    carvedilol
    1 interaction

    Monitor/Modify Tx

    sparsentan + carvedilol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • celecoxib
  • Filspari (sparsentan)
    +
    celecoxib
    1 interaction

    Monitor/Modify Tx

    sparsentan + celecoxib

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • chloroprocaine
  • Filspari (sparsentan)
    +
    chloroprocaine
    1 interaction

    Monitor/Modify Tx

    sparsentan + chloroprocaine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • chlorothiazide
  • Filspari (sparsentan)
    +
    chlorothiazide
    1 interaction

    Monitor/Modify Tx

    sparsentan + chlorothiazide

    monitor BP, renal fxn: combo may incr. risk of nephrotoxicity, hypotension, including orthostasis, syncope (additive effects)

  • chlorpromazine
  • Filspari (sparsentan)
    +
    chlorpromazine
    1 interaction

    Monitor/Modify Tx

    sparsentan + chlorpromazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • chlorthalidone
  • Filspari (sparsentan)
    +
    chlorthalidone
    1 interaction

    Monitor/Modify Tx

    sparsentan + chlorthalidone

    monitor BP, renal fxn: combo may incr. risk of nephrotoxicity, hypotension, including orthostasis, syncope (additive effects)

  • cilostazol
  • Filspari (sparsentan)
    +
    cilostazol
    1 interaction

    Monitor/Modify Tx

    sparsentan + cilostazol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • ciprofloxacin
  • Filspari (sparsentan)
    +
    ciprofloxacin
    1 interaction

    Monitor/Modify Tx

    sparsentan + ciprofloxacin

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • cisplatin
  • Filspari (sparsentan)
    +
    cisplatin
    1 interaction

    Monitor/Modify Tx

    sparsentan + cisplatin

    monitor CBC, renal fxn, ototoxicity: combo may incr. cisplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • clevidipine
  • Filspari (sparsentan)
    +
    clevidipine
    1 interaction

    Monitor/Modify Tx

    sparsentan + clevidipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • clindamycin
  • Filspari (sparsentan)
    +
    clindamycin
    1 interaction

    Monitor/Modify Tx

    sparsentan + clindamycin

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • clofazimine
  • Filspari (sparsentan)
    +
    clofazimine
    1 interaction

    Monitor/Modify Tx

    sparsentan + clofazimine

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • clomipramine
  • Filspari (sparsentan)
    +
    clomipramine
    1 interaction

    Monitor/Modify Tx

    sparsentan + clomipramine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • clonidine
  • Filspari (sparsentan)
    +
    clonidine
    1 interaction

    Monitor/Modify Tx

    sparsentan + clonidine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • clozapine
  • Filspari (sparsentan)
    +
    clozapine
    1 interaction

    Monitor/Modify Tx

    sparsentan + clozapine

    monitor BP, HR: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • codeine
  • Filspari (sparsentan)
    +
    codeine
    1 interaction

    Monitor/Modify Tx

    sparsentan + codeine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • coenzyme Q-10
  • Filspari (sparsentan)
    +
    coenzyme Q-10
    1 interaction

    Monitor/Modify Tx

    sparsentan + coenzyme Q-10

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • colistimethate
  • Filspari (sparsentan)
    +
    colistimethate
    1 interaction

    Monitor/Modify Tx

    sparsentan + colistimethate

    monitor renal fxn: combo may incr. colistimethate levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • conivaptan
  • Filspari (sparsentan)
    +
    conivaptan
    1 interaction

    Monitor/Modify Tx

    sparsentan + conivaptan

    monitor BP, potassium, renal fxn during and x7 days after conivaptan tx: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • copper histidinate
  • Filspari (sparsentan)
    +
    copper histidinate
    1 interaction

    Monitor/Modify Tx

    sparsentan + copper histidinate

    monitor renal fxn, electrolytes: combo may incr. risk of nephrotoxicity (additive effects)

  • creatine
  • Filspari (sparsentan)
    +
    creatine
    1 interaction

    Monitor/Modify Tx

    sparsentan + creatine

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • crizotinib
  • Filspari (sparsentan)
    +
    crizotinib
    1 interaction

    Monitor/Modify Tx

    sparsentan + crizotinib

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • cyclophosphamide
  • Filspari (sparsentan)
    +
    cyclophosphamide
    1 interaction

    Monitor/Modify Tx

    sparsentan + cyclophosphamide

    monitor CBC, renal, cardiac fxn: combo may incr. cyclophosphamide and active metabolite levels, risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, other adverse effects (hepatic metabolism possibly induced, incr. active metabolite formation; additive effects)

  • cyclosporine
  • Filspari (sparsentan)
    +
    cyclosporine
    1 interaction

    Monitor/Modify Tx

    sparsentan + cyclosporine

    monitor cyclosporine levels, renal fxn, BP, potassium: combo may incr. levels or both drugs, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, serious infection, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport possibly inhibited, additive effects)

  • cytomegalovirus immune globulin
  • Filspari (sparsentan)
    +
    cytomegalovirus immune globulin
    1 interaction

    Monitor/Modify Tx

    sparsentan + cytomegalovirus immune globulin

    monitor renal fxn; use lowest cytomegalovirus immune globulin concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • danazol
  • Filspari (sparsentan)
    +
    danazol
    1 interaction

    Monitor/Modify Tx

    sparsentan + danazol

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • dapagliflozin
  • Filspari (sparsentan)
    +
    dapagliflozin
    1 interaction

    Monitor/Modify Tx

    sparsentan + dapagliflozin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • darunavir
  • Filspari (sparsentan)
    +
    darunavir
    1 interaction

    Monitor/Modify Tx

    sparsentan + darunavir

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • decitabine
  • Filspari (sparsentan)
    +
    decitabine
    1 interaction

    Monitor/Modify Tx

    sparsentan + decitabine

    monitor potassium w/ IV decitabine use: combo may incr. risk of hyperkalemia (additive effects)

  • deferasirox
  • Filspari (sparsentan)
    +
    deferasirox
    1 interaction

    Monitor/Modify Tx

    sparsentan + deferasirox

    monitor CBC, renal fxn, ototoxicity: combo may incr. deferasirox levels, risk of myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • deferoxamine
  • Filspari (sparsentan)
    +
    deferoxamine
    1 interaction

    Monitor/Modify Tx

    sparsentan + deferoxamine

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • denileukin diftitox
  • Filspari (sparsentan)
    +
    denileukin diftitox
    1 interaction

    Monitor/Modify Tx

    sparsentan + denileukin diftitox

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • desflurane
  • Filspari (sparsentan)
    +
    desflurane
    1 interaction

    Monitor/Modify Tx

    sparsentan + desflurane

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • desipramine
  • Filspari (sparsentan)
    +
    desipramine
    1 interaction

    Monitor/Modify Tx

    sparsentan + desipramine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • dexmedetomidine
  • Filspari (sparsentan)
    +
    dexmedetomidine
    1 interaction

    Monitor/Modify Tx

    sparsentan + dexmedetomidine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • dexmedetomidine injection
  • Filspari (sparsentan)
    +
    dexmedetomidine injection
    1 interaction

    Monitor/Modify Tx

    sparsentan + dexmedetomidine injection

    monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

  • diclofenac
  • Filspari (sparsentan)
    +
    diclofenac
    1 interaction

    Monitor/Modify Tx

    sparsentan + diclofenac

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • diclofenac topical
  • Filspari (sparsentan)
    +
    diclofenac topical
    1 interaction

    Monitor/Modify Tx

    sparsentan + diclofenac topical

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • diflunisal
  • Filspari (sparsentan)
    +
    diflunisal
    1 interaction

    Monitor/Modify Tx

    sparsentan + diflunisal

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • digoxin
  • Filspari (sparsentan)
    +
    digoxin
    1 interaction

    Monitor/Modify Tx

    sparsentan + digoxin

    monitor digoxin levels, HR; decr. digoxin frequency or dose by 15-30%: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (P-gp-mediated transport possibly inhibited)

  • dihydrocodeine
  • Filspari (sparsentan)
    +
    dihydrocodeine
    1 interaction

    Monitor/Modify Tx

    sparsentan + dihydrocodeine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • diltiazem
  • Filspari (sparsentan)
    +
    diltiazem
    1 interaction

    Monitor/Modify Tx

    sparsentan + diltiazem

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • dinutuximab
  • Filspari (sparsentan)
    +
    dinutuximab
    1 interaction

    Monitor/Modify Tx

    sparsentan + dinutuximab

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • dipyridamole
  • Filspari (sparsentan)
    +
    dipyridamole
    1 interaction

    Monitor/Modify Tx

    sparsentan + dipyridamole

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • doxazosin
  • Filspari (sparsentan)
    +
    doxazosin
    1 interaction

    Monitor/Modify Tx

    sparsentan + doxazosin

    monitor BP, especially during doxazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • doxepin
  • Filspari (sparsentan)
    +
    doxepin
    1 interaction

    Monitor/Modify Tx

    sparsentan + doxepin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • dronabinol
  • Filspari (sparsentan)
    +
    dronabinol
    1 interaction

    Monitor/Modify Tx

    sparsentan + dronabinol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • dronedarone
  • Filspari (sparsentan)
    +
    dronedarone
    1 interaction

    Monitor/Modify Tx

    sparsentan + dronedarone

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • drospirenone (contraceptive)
  • Filspari (sparsentan)
    +
    drospirenone (contraceptive)
    1 interaction

    Monitor/Modify Tx

    sparsentan + drospirenone (contraceptive)

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • drospirenone (hormone replacement)
  • Filspari (sparsentan)
    +
    drospirenone (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    sparsentan + drospirenone (hormone replacement)

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • duloxetine
  • Filspari (sparsentan)
    +
    duloxetine
    1 interaction

    Monitor/Modify Tx

    sparsentan + duloxetine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • duvelisib
  • Filspari (sparsentan)
    +
    duvelisib
    1 interaction

    Monitor/Modify Tx

    sparsentan + duvelisib

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • edoxaban
  • Filspari (sparsentan)
    +
    edoxaban
    1 interaction

    Monitor/Modify Tx

    sparsentan + edoxaban

    monitor bleeding s/sx: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

  • empagliflozin
  • Filspari (sparsentan)
    +
    empagliflozin
    1 interaction

    Monitor/Modify Tx

    sparsentan + empagliflozin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • enfortumab vedotin
  • Filspari (sparsentan)
    +
    enfortumab vedotin
    1 interaction

    Monitor/Modify Tx

    sparsentan + enfortumab vedotin

    if also combined w/ strong CYP3A4 inhibitor, monitor CBC, glucose: combo may incr. enfortumab vedotin levels, risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects (P-gp-mediated transport possibly inhibited)

  • entacapone
  • Filspari (sparsentan)
    +
    entacapone
    1 interaction

    Monitor/Modify Tx

    sparsentan + entacapone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • entrectinib
  • Filspari (sparsentan)
    +
    entrectinib
    1 interaction

    Monitor/Modify Tx

    sparsentan + entrectinib

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • eplerenone
  • Filspari (sparsentan)
    +
    eplerenone
    1 interaction

    Monitor/Modify Tx

    sparsentan + eplerenone

    monitor potassium, renal fxn, BP: combo may incr. risk of hyperkalemia, hypotension, including orthostasis, syncope (additive effects)

  • epoprostenol
  • Filspari (sparsentan)
    +
    epoprostenol
    1 interaction

    Monitor/Modify Tx

    sparsentan + epoprostenol

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • ertugliflozin
  • Filspari (sparsentan)
    +
    ertugliflozin
    1 interaction

    Monitor/Modify Tx

    sparsentan + ertugliflozin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • erythromycin
  • Filspari (sparsentan)
    +
    erythromycin
    1 interaction

    Monitor/Modify Tx

    sparsentan + erythromycin

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • esmolol
  • Filspari (sparsentan)
    +
    esmolol
    1 interaction

    Monitor/Modify Tx

    sparsentan + esmolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • ethacrynic acid
  • Filspari (sparsentan)
    +
    ethacrynic acid
    1 interaction

    Monitor/Modify Tx

    sparsentan + ethacrynic acid

    monitor BP, renal fxn: combo may incr. risk of nephrotoxicity, hypotension, including orthostasis, syncope (additive effects)

  • ethanol (alcoholic beverage)
  • Filspari (sparsentan)
    +
    ethanol (alcoholic beverage)
    1 interaction

    Monitor/Modify Tx

    sparsentan + ethanol (alcoholic beverage)

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • ethanol injection
  • Filspari (sparsentan)
    +
    ethanol injection
    1 interaction

    Monitor/Modify Tx

    sparsentan + ethanol injection

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • etodolac
  • Filspari (sparsentan)
    +
    etodolac
    1 interaction

    Monitor/Modify Tx

    sparsentan + etodolac

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • etripamil nasal
  • Filspari (sparsentan)
    +
    etripamil nasal
    1 interaction

    Monitor/Modify Tx

    sparsentan + etripamil nasal

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • everolimus
  • Filspari (sparsentan)
    +
    everolimus
    1 interaction

    Monitor/Modify Tx

    sparsentan + everolimus

    TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC, renal fxn; OTHER INDICATIONS: monitor CBC, renal fxn: combo may incr. everolimus levels, risk of myelosuppression, nephrotoxicity, other adverse effects (P-gp-mediated transport possibly inhibited, additive effects)

  • fedratinib
  • Filspari (sparsentan)
    +
    fedratinib
    1 interaction

    Monitor/Modify Tx

    sparsentan + fedratinib

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • felodipine
  • Filspari (sparsentan)
    +
    felodipine
    1 interaction

    Monitor/Modify Tx

    sparsentan + felodipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • fenoldopam
  • Filspari (sparsentan)
    +
    fenoldopam
    1 interaction

    Monitor/Modify Tx

    sparsentan + fenoldopam

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • fenoprofen
  • Filspari (sparsentan)
    +
    fenoprofen
    1 interaction

    Monitor/Modify Tx

    sparsentan + fenoprofen

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • fentanyl
  • Filspari (sparsentan)
    +
    fentanyl
    1 interaction

    Monitor/Modify Tx

    sparsentan + fentanyl

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • ferumoxytol
  • Filspari (sparsentan)
    +
    ferumoxytol
    1 interaction

    Monitor/Modify Tx

    sparsentan + ferumoxytol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • finerenone
  • Filspari (sparsentan)
    +
    finerenone
    1 interaction

    Monitor/Modify Tx

    sparsentan + finerenone

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • flaxseed
  • Filspari (sparsentan)
    +
    flaxseed
    1 interaction

    Monitor/Modify Tx

    sparsentan + flaxseed

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • flibanserin
  • Filspari (sparsentan)
    +
    flibanserin
    1 interaction

    Monitor/Modify Tx

    sparsentan + flibanserin

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • fluconazole
  • Filspari (sparsentan)
    +
    fluconazole
    1 interaction

    Monitor/Modify Tx

    sparsentan + fluconazole

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • flucytosine
  • Filspari (sparsentan)
    +
    flucytosine
    1 interaction

    Monitor/Modify Tx

    sparsentan + flucytosine

    monitor CBC, renal fxn, flucytosine levels: combo may incr. flucytosine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • fluphenazine
  • Filspari (sparsentan)
    +
    fluphenazine
    1 interaction

    Monitor/Modify Tx

    sparsentan + fluphenazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • flurbiprofen
  • Filspari (sparsentan)
    +
    flurbiprofen
    1 interaction

    Monitor/Modify Tx

    sparsentan + flurbiprofen

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • fluvastatin
  • Filspari (sparsentan)
    +
    fluvastatin
    1 interaction

    Monitor/Modify Tx

    sparsentan + fluvastatin

    monitor CK, myopathy sx: combo may incr. fluvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport possibly inhibited)

  • fosamprenavir
  • Filspari (sparsentan)
    +
    fosamprenavir
    1 interaction

    Monitor/Modify Tx

    sparsentan + fosamprenavir

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • foslevodopa
  • Filspari (sparsentan)
    +
    foslevodopa
    1 interaction

    Monitor/Modify Tx

    sparsentan + foslevodopa

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • furosemide
  • Filspari (sparsentan)
    +
    furosemide
    1 interaction

    Monitor/Modify Tx

    sparsentan + furosemide

    monitor BP, renal fxn: combo may incr. risk of nephrotoxicity, hypotension, including orthostasis, syncope (additive effects)

  • garlic
  • Filspari (sparsentan)
    +
    garlic
    1 interaction

    Monitor/Modify Tx

    sparsentan + garlic

    monitor BP w/ supplemental garlic; dietary intake OK: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • gilteritinib
  • Filspari (sparsentan)
    +
    gilteritinib
    1 interaction

    Monitor/Modify Tx

    sparsentan + gilteritinib

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • grapefruit
  • Filspari (sparsentan)
    +
    grapefruit
    1 interaction

    Monitor/Modify Tx

    sparsentan + grapefruit

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (GI metabolism inhibited)

  • guanfacine
  • Filspari (sparsentan)
    +
    guanfacine
    1 interaction

    Monitor/Modify Tx

    sparsentan + guanfacine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • haloperidol
  • Filspari (sparsentan)
    +
    haloperidol
    1 interaction

    Monitor/Modify Tx

    sparsentan + haloperidol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • heparin
  • Filspari (sparsentan)
    +
    heparin
    1 interaction

    Monitor/Modify Tx

    sparsentan + heparin

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • hydralazine
  • Filspari (sparsentan)
    +
    hydralazine
    1 interaction

    Monitor/Modify Tx

    sparsentan + hydralazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • hydrochlorothiazide
  • Filspari (sparsentan)
    +
    hydrochlorothiazide
    1 interaction

    Monitor/Modify Tx

    sparsentan + hydrochlorothiazide

    monitor BP, renal fxn: combo may incr. risk of nephrotoxicity, hypotension, including orthostasis, syncope (additive effects)

  • hydrocodone
  • Filspari (sparsentan)
    +
    hydrocodone
    1 interaction

    Monitor/Modify Tx

    sparsentan + hydrocodone

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • hydromorphone
  • Filspari (sparsentan)
    +
    hydromorphone
    1 interaction

    Monitor/Modify Tx

    sparsentan + hydromorphone

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • hydroxocobalamin IV
  • Filspari (sparsentan)
    +
    hydroxocobalamin IV
    1 interaction

    Monitor/Modify Tx

    sparsentan + hydroxocobalamin IV

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • ibuprofen
  • Filspari (sparsentan)
    +
    ibuprofen
    1 interaction

    Monitor/Modify Tx

    sparsentan + ibuprofen

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • ibuprofen lysine
  • Filspari (sparsentan)
    +
    ibuprofen lysine
    1 interaction

    Monitor/Modify Tx

    sparsentan + ibuprofen lysine

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • ifosfamide
  • Filspari (sparsentan)
    +
    ifosfamide
    1 interaction

    Monitor/Modify Tx

    sparsentan + ifosfamide

    monitor CBC, renal, cardiac fxn; consider ifosfamide dose adjustment: combo may incr. ifosfamide active and toxic metabolite levels, risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, cardiotoxicity, other adverse effects (hepatic metabolism possibly induced, incr. metabolite formation; additive effects)

  • iloperidone
  • Filspari (sparsentan)
    +
    iloperidone
    1 interaction

    Monitor/Modify Tx

    sparsentan + iloperidone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • iloprost
  • Filspari (sparsentan)
    +
    iloprost
    1 interaction

    Monitor/Modify Tx

    sparsentan + iloprost

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • imatinib
  • Filspari (sparsentan)
    +
    imatinib
    1 interaction

    Monitor/Modify Tx

    sparsentan + imatinib

    monitor BP, potassium, renal function: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • imipramine
  • Filspari (sparsentan)
    +
    imipramine
    1 interaction

    Monitor/Modify Tx

    sparsentan + imipramine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • immune globulin
  • Filspari (sparsentan)
    +
    immune globulin
    1 interaction

    Monitor/Modify Tx

    sparsentan + immune globulin

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • indapamide
  • Filspari (sparsentan)
    +
    indapamide
    1 interaction

    Monitor/Modify Tx

    sparsentan + indapamide

    monitor BP, renal fxn: combo may incr. risk of nephrotoxicity, hypotension, including orthostasis, syncope (additive effects)

  • indomethacin
  • Filspari (sparsentan)
    +
    indomethacin
    1 interaction

    Monitor/Modify Tx

    sparsentan + indomethacin

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • iodixanol
  • Filspari (sparsentan)
    +
    iodixanol
    1 interaction

    Monitor/Modify Tx

    sparsentan + iodixanol

    monitor renal function: combo may incr. risk of nephrotoxicity (additive effects)

  • iohexol
  • Filspari (sparsentan)
    +
    iohexol
    1 interaction

    Monitor/Modify Tx

    sparsentan + iohexol

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • iomeprol
  • Filspari (sparsentan)
    +
    iomeprol
    1 interaction

    Monitor/Modify Tx

    sparsentan + iomeprol

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • iopamidol
  • Filspari (sparsentan)
    +
    iopamidol
    1 interaction

    Monitor/Modify Tx

    sparsentan + iopamidol

    if IV iopamidol use, monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • iopromide
  • Filspari (sparsentan)
    +
    iopromide
    1 interaction

    Monitor/Modify Tx

    sparsentan + iopromide

    monitor renal function: combo may incr. risk of nephrotoxicity (additive effects)

  • iothalamate meglumine
  • Filspari (sparsentan)
    +
    iothalamate meglumine
    1 interaction

    Monitor/Modify Tx

    sparsentan + iothalamate meglumine

    if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)

  • ioversol
  • Filspari (sparsentan)
    +
    ioversol
    1 interaction

    Monitor/Modify Tx

    sparsentan + ioversol

    monitor renal function: combo may incr. risk of nephrotoxicity (additive effects)

  • irinotecan
  • Filspari (sparsentan)
    +
    irinotecan
    1 interaction

    Monitor/Modify Tx

    sparsentan + irinotecan

    monitor CBC: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (BCRP-mediated transport possibly inhibited)

  • iron sucrose
  • Filspari (sparsentan)
    +
    iron sucrose
    1 interaction

    Monitor/Modify Tx

    sparsentan + iron sucrose

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • isavuconazonium
  • Filspari (sparsentan)
    +
    isavuconazonium
    1 interaction

    Monitor/Modify Tx

    sparsentan + isavuconazonium

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • isocarboxazid
  • Filspari (sparsentan)
    +
    isocarboxazid
    1 interaction

    Monitor/Modify Tx

    sparsentan + isocarboxazid

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • isoflurane
  • Filspari (sparsentan)
    +
    isoflurane
    1 interaction

    Monitor/Modify Tx

    sparsentan + isoflurane

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • isosorbide dinitrate
  • Filspari (sparsentan)
    +
    isosorbide dinitrate
    1 interaction

    Monitor/Modify Tx

    sparsentan + isosorbide dinitrate

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • isosorbide mononitrate
  • Filspari (sparsentan)
    +
    isosorbide mononitrate
    1 interaction

    Monitor/Modify Tx

    sparsentan + isosorbide mononitrate

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • isradipine
  • Filspari (sparsentan)
    +
    isradipine
    1 interaction

    Monitor/Modify Tx

    sparsentan + isradipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • ketoprofen
  • Filspari (sparsentan)
    +
    ketoprofen
    1 interaction

    Monitor/Modify Tx

    sparsentan + ketoprofen

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • ketorolac
  • Filspari (sparsentan)
    +
    ketorolac
    1 interaction

    Monitor/Modify Tx

    sparsentan + ketorolac

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • labetalol
  • Filspari (sparsentan)
    +
    labetalol
    1 interaction

    Monitor/Modify Tx

    sparsentan + labetalol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • landiolol
  • Filspari (sparsentan)
    +
    landiolol
    1 interaction

    Monitor/Modify Tx

    sparsentan + landiolol

    monitor BP, potassium, especially if renal impairment: combo may incr. risk of hypotension (including orthostasis, syncope), hyperkalemia (additive effects)

  • lapatinib
  • Filspari (sparsentan)
    +
    lapatinib
    1 interaction

    Monitor/Modify Tx

    sparsentan + lapatinib

    monitor ECG: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (BCRP-mediated transport possibly inhibited)

  • lefamulin
  • Filspari (sparsentan)
    +
    lefamulin
    1 interaction

    Monitor/Modify Tx

    sparsentan + lefamulin

    ORAL LEFAMULIN: monitor BP, potassium, renal fxn; IV lefamulin use OK: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • lenacapavir
  • Filspari (sparsentan)
    +
    lenacapavir
    1 interaction

    Monitor/Modify Tx

    sparsentan + lenacapavir

    monitor BP, potassium, renal fxn during and x9mo after lenacapavir tx: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • lenvatinib
  • Filspari (sparsentan)
    +
    lenvatinib
    1 interaction

    Monitor/Modify Tx

    sparsentan + lenvatinib

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • letermovir
  • Filspari (sparsentan)
    +
    letermovir
    1 interaction

    Monitor/Modify Tx

    sparsentan + letermovir

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • levobunolol ophthalmic
  • Filspari (sparsentan)
    +
    levobunolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    sparsentan + levobunolol ophthalmic

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • levodopa
  • Filspari (sparsentan)
    +
    levodopa
    1 interaction

    Monitor/Modify Tx

    sparsentan + levodopa

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • levorphanol
  • Filspari (sparsentan)
    +
    levorphanol
    1 interaction

    Monitor/Modify Tx

    sparsentan + levorphanol

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • lidocaine
  • Filspari (sparsentan)
    +
    lidocaine
    1 interaction

    Monitor/Modify Tx

    sparsentan + lidocaine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • lifileucel
  • Filspari (sparsentan)
    +
    lifileucel
    1 interaction

    Monitor/Modify Tx

    sparsentan + lifileucel

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • lithium
  • Filspari (sparsentan)
    +
    lithium
    1 interaction

    Monitor/Modify Tx

    sparsentan + lithium

    monitor lithium levels, renal fxn: combo may incr. lithium levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • lomustine
  • Filspari (sparsentan)
    +
    lomustine
    1 interaction

    Monitor/Modify Tx

    sparsentan + lomustine

    monitor CBC, renal fxn: combo may incr. lomustine levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • loxapine
  • Filspari (sparsentan)
    +
    loxapine
    1 interaction

    Monitor/Modify Tx

    sparsentan + loxapine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • lubiprostone
  • Filspari (sparsentan)
    +
    lubiprostone
    1 interaction

    Monitor/Modify Tx

    sparsentan + lubiprostone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • lumateperone
  • Filspari (sparsentan)
    +
    lumateperone
    1 interaction

    Monitor/Modify Tx

    sparsentan + lumateperone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • lurasidone
  • Filspari (sparsentan)
    +
    lurasidone
    1 interaction

    Monitor/Modify Tx

    sparsentan + lurasidone

    monitor BP; consider lowest lurasidone start dose, titrate slowly: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • lutetium Lu 177 vipivotide tetraxetan
  • Filspari (sparsentan)
    +
    lutetium Lu 177 vipivotide tetraxetan
    1 interaction

    Monitor/Modify Tx

    sparsentan + lutetium Lu 177 vipivotide tetraxetan

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • magnesium carbonate
  • Filspari (sparsentan)
    +
    magnesium carbonate
    1 interaction

    Monitor/Modify Tx

    sparsentan + magnesium carbonate

    separate admin. by at least 2h: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • magnesium citrate
  • Filspari (sparsentan)
    +
    magnesium citrate
    1 interaction

    Monitor/Modify Tx

    sparsentan + magnesium citrate

    monitor renal fxn, especially if magnesium citrate bowel prep use: combo may incr. risk of nephrotoxicity (additive effects)

  • magnesium hydroxide
  • Filspari (sparsentan)
    +
    magnesium hydroxide
    1 interaction

    Monitor/Modify Tx

    sparsentan + magnesium hydroxide

    separate admin. by at least 2h: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • magnesium oxide
  • Filspari (sparsentan)
    +
    magnesium oxide
    1 interaction

    Monitor/Modify Tx

    sparsentan + magnesium oxide

    separate admin. by at least 2h: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • magnesium salicylate
  • Filspari (sparsentan)
    +
    magnesium salicylate
    1 interaction

    Monitor/Modify Tx

    sparsentan + magnesium salicylate

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • magnesium sulfate
  • Filspari (sparsentan)
    +
    magnesium sulfate
    1 interaction

    Monitor/Modify Tx

    sparsentan + magnesium sulfate

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • maraviroc
  • Filspari (sparsentan)
    +
    maraviroc
    1 interaction

    Monitor/Modify Tx

    sparsentan + maraviroc

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • mavorixafor
  • Filspari (sparsentan)
    +
    mavorixafor
    1 interaction

    Monitor/Modify Tx

    sparsentan + mavorixafor

    monitor ECG: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport possibly inhibited)

  • meclofenamate
  • Filspari (sparsentan)
    +
    meclofenamate
    1 interaction

    Monitor/Modify Tx

    sparsentan + meclofenamate

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • mefenamic acid
  • Filspari (sparsentan)
    +
    mefenamic acid
    1 interaction

    Monitor/Modify Tx

    sparsentan + mefenamic acid

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • meloxicam
  • Filspari (sparsentan)
    +
    meloxicam
    1 interaction

    Monitor/Modify Tx

    sparsentan + meloxicam

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • mepivacaine
  • Filspari (sparsentan)
    +
    mepivacaine
    1 interaction

    Monitor/Modify Tx

    sparsentan + mepivacaine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • mesalamine
  • Filspari (sparsentan)
    +
    mesalamine
    1 interaction

    Monitor/Modify Tx

    sparsentan + mesalamine

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • mesalamine rectal
  • Filspari (sparsentan)
    +
    mesalamine rectal
    1 interaction

    Monitor/Modify Tx

    sparsentan + mesalamine rectal

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • methadone
  • Filspari (sparsentan)
    +
    methadone
    1 interaction

    Monitor/Modify Tx

    sparsentan + methadone

    monitor BP: combo may decr. methadone levels, efficacy; may incr. risk of severe hypotension, including orthostasis, syncope (hepatic metabolism induced; additive effects)

  • methohexital
  • Filspari (sparsentan)
    +
    methohexital
    1 interaction

    Monitor/Modify Tx

    sparsentan + methohexital

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • methyldopa
  • Filspari (sparsentan)
    +
    methyldopa
    1 interaction

    Monitor/Modify Tx

    sparsentan + methyldopa

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • methylene blue injection
  • Filspari (sparsentan)
    +
    methylene blue injection
    1 interaction

    Monitor/Modify Tx

    sparsentan + methylene blue injection

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • metolazone
  • Filspari (sparsentan)
    +
    metolazone
    1 interaction

    Monitor/Modify Tx

    sparsentan + metolazone

    monitor BP, renal fxn: combo may incr. risk of nephrotoxicity, hypotension, including orthostasis, syncope (additive effects)

  • metoprolol
  • Filspari (sparsentan)
    +
    metoprolol
    1 interaction

    Monitor/Modify Tx

    sparsentan + metoprolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • midazolam
  • Filspari (sparsentan)
    +
    midazolam
    1 interaction

    Monitor/Modify Tx

    sparsentan + midazolam

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • milrinone
  • Filspari (sparsentan)
    +
    milrinone
    1 interaction

    Monitor/Modify Tx

    sparsentan + milrinone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • milsaperidone
  • Filspari (sparsentan)
    +
    milsaperidone
    1 interaction

    Monitor/Modify Tx

    sparsentan + milsaperidone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • minoxidil
  • Filspari (sparsentan)
    +
    minoxidil
    1 interaction

    Monitor/Modify Tx

    sparsentan + minoxidil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • mirtazapine
  • Filspari (sparsentan)
    +
    mirtazapine
    1 interaction

    Monitor/Modify Tx

    sparsentan + mirtazapine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • mitomycin
  • Filspari (sparsentan)
    +
    mitomycin
    1 interaction

    Monitor/Modify Tx

    sparsentan + mitomycin

    monitor renal fxn; risk may be lower w/ intravesical mitomycin administration: combo may incr. risk of nephrotoxicity (additive effects)

  • mitoxantrone
  • Filspari (sparsentan)
    +
    mitoxantrone
    1 interaction

    Monitor/Modify Tx

    sparsentan + mitoxantrone

    monitor CBC, cardiac fxn, incl. LVEF: combo may incr. mitoxantrone levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (BCRP-mediated transport possibly inhibited)

  • molindone
  • Filspari (sparsentan)
    +
    molindone
    1 interaction

    Monitor/Modify Tx

    sparsentan + molindone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • morphine
  • Filspari (sparsentan)
    +
    morphine
    1 interaction

    Monitor/Modify Tx

    sparsentan + morphine

    monitor BP, respiratory rate; consider decr. dose of one or both drugs: combo may incr. morphine levels, risk of CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), other adverse effects (P-gp-mediated transport possibly inhibited, additive effects)

  • nabumetone
  • Filspari (sparsentan)
    +
    nabumetone
    1 interaction

    Monitor/Modify Tx

    sparsentan + nabumetone

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • nadolol
  • Filspari (sparsentan)
    +
    nadolol
    1 interaction

    Monitor/Modify Tx

    sparsentan + nadolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nalbuphine
  • Filspari (sparsentan)
    +
    nalbuphine
    1 interaction

    Monitor/Modify Tx

    sparsentan + nalbuphine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • naproxen
  • Filspari (sparsentan)
    +
    naproxen
    1 interaction

    Monitor/Modify Tx

    sparsentan + naproxen

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • nattokinase
  • Filspari (sparsentan)
    +
    nattokinase
    1 interaction

    Monitor/Modify Tx

    sparsentan + nattokinase

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • naxitamab
  • Filspari (sparsentan)
    +
    naxitamab
    1 interaction

    Monitor/Modify Tx

    sparsentan + naxitamab

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nebivolol
  • Filspari (sparsentan)
    +
    nebivolol
    1 interaction

    Monitor/Modify Tx

    sparsentan + nebivolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • neomycin
  • Filspari (sparsentan)
    +
    neomycin
    1 interaction

    Monitor/Modify Tx

    sparsentan + neomycin

    if compromised gut wall allows for neomycin absorption, monitor renal fxn, ototoxicity: combo may incr. neomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • netupitant
  • Filspari (sparsentan)
    +
    netupitant
    1 interaction

    Monitor/Modify Tx

    sparsentan + netupitant

    monitor BP, potassium, renal fxn during and x1wk after (fos)netupitant tx: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • niacin (vitamin B3)
  • Filspari (sparsentan)
    +
    niacin (vitamin B3)
    1 interaction

    Monitor/Modify Tx

    sparsentan + niacin (vitamin B3)

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nicardipine
  • Filspari (sparsentan)
    +
    nicardipine
    1 interaction

    Monitor/Modify Tx

    sparsentan + nicardipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nifedipine
  • Filspari (sparsentan)
    +
    nifedipine
    1 interaction

    Monitor/Modify Tx

    sparsentan + nifedipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nilotinib
  • Filspari (sparsentan)
    +
    nilotinib
    1 interaction

    Monitor/Modify Tx

    sparsentan + nilotinib

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • nimodipine
  • Filspari (sparsentan)
    +
    nimodipine
    1 interaction

    Monitor/Modify Tx

    sparsentan + nimodipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nirogacestat
  • Filspari (sparsentan)
    +
    nirogacestat
    1 interaction

    Monitor/Modify Tx

    sparsentan + nirogacestat

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • nisoldipine
  • Filspari (sparsentan)
    +
    nisoldipine
    1 interaction

    Monitor/Modify Tx

    sparsentan + nisoldipine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nitric oxide
  • Filspari (sparsentan)
    +
    nitric oxide
    1 interaction

    Monitor/Modify Tx

    sparsentan + nitric oxide

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nitrite
  • Filspari (sparsentan)
    +
    nitrite
    1 interaction

    Monitor/Modify Tx

    sparsentan + nitrite

    monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

  • nitroglycerin
  • Filspari (sparsentan)
    +
    nitroglycerin
    1 interaction

    Monitor/Modify Tx

    sparsentan + nitroglycerin

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • nitroprusside
  • Filspari (sparsentan)
    +
    nitroprusside
    1 interaction

    Monitor/Modify Tx

    sparsentan + nitroprusside

    monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

  • nortriptyline
  • Filspari (sparsentan)
    +
    nortriptyline
    1 interaction

    Monitor/Modify Tx

    sparsentan + nortriptyline

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • nusinersen
  • Filspari (sparsentan)
    +
    nusinersen
    1 interaction

    Monitor/Modify Tx

    sparsentan + nusinersen

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • obinutuzumab
  • Filspari (sparsentan)
    +
    obinutuzumab
    1 interaction

    Monitor/Modify Tx

    sparsentan + obinutuzumab

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • olanzapine
  • Filspari (sparsentan)
    +
    olanzapine
    1 interaction

    Monitor/Modify Tx

    sparsentan + olanzapine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • oliceridine
  • Filspari (sparsentan)
    +
    oliceridine
    1 interaction

    Monitor/Modify Tx

    sparsentan + oliceridine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • olsalazine
  • Filspari (sparsentan)
    +
    olsalazine
    1 interaction

    Monitor/Modify Tx

    sparsentan + olsalazine

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • opicapone
  • Filspari (sparsentan)
    +
    opicapone
    1 interaction

    Monitor/Modify Tx

    sparsentan + opicapone

    monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • opium
  • Filspari (sparsentan)
    +
    opium
    1 interaction

    Monitor/Modify Tx

    sparsentan + opium

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • oxaprozin
  • Filspari (sparsentan)
    +
    oxaprozin
    1 interaction

    Monitor/Modify Tx

    sparsentan + oxaprozin

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • oxazepam
  • Filspari (sparsentan)
    +
    oxazepam
    1 interaction

    Monitor/Modify Tx

    sparsentan + oxazepam

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • oxycodone
  • Filspari (sparsentan)
    +
    oxycodone
    1 interaction

    Monitor/Modify Tx

    sparsentan + oxycodone

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • oxymorphone
  • Filspari (sparsentan)
    +
    oxymorphone
    1 interaction

    Monitor/Modify Tx

    sparsentan + oxymorphone

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • paliperidone
  • Filspari (sparsentan)
    +
    paliperidone
    1 interaction

    Monitor/Modify Tx

    sparsentan + paliperidone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • palopegteriparatide
  • Filspari (sparsentan)
    +
    palopegteriparatide
    1 interaction

    Monitor/Modify Tx

    sparsentan + palopegteriparatide

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • pamidronate
  • Filspari (sparsentan)
    +
    pamidronate
    1 interaction

    Monitor/Modify Tx

    sparsentan + pamidronate

    monitor renal fxn: combo may incr. pamidronate levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • paromomycin
  • Filspari (sparsentan)
    +
    paromomycin
    1 interaction

    Monitor/Modify Tx

    sparsentan + paromomycin

    if compromised gut wall allows for paromomycin absorption, monitor renal fxn, ototoxicity: combo may incr. paromomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • pemetrexed
  • Filspari (sparsentan)
    +
    pemetrexed
    1 interaction

    Monitor/Modify Tx

    sparsentan + pemetrexed

    monitor CBC, renal fxn: combo may incr. pemetrexed levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • penicillamine
  • Filspari (sparsentan)
    +
    penicillamine
    1 interaction

    Monitor/Modify Tx

    sparsentan + penicillamine

    monitor CBC, renal fxn: combo may incr. penicillamine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • pentazocine
  • Filspari (sparsentan)
    +
    pentazocine
    1 interaction

    Monitor/Modify Tx

    sparsentan + pentazocine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • pentostatin
  • Filspari (sparsentan)
    +
    pentostatin
    1 interaction

    Monitor/Modify Tx

    sparsentan + pentostatin

    monitor CBC, renal fxn: combo may incr. pentostatin levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • perphenazine
  • Filspari (sparsentan)
    +
    perphenazine
    1 interaction

    Monitor/Modify Tx

    sparsentan + perphenazine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • phenelzine
  • Filspari (sparsentan)
    +
    phenelzine
    1 interaction

    Monitor/Modify Tx

    sparsentan + phenelzine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • phenoxybenzamine
  • Filspari (sparsentan)
    +
    phenoxybenzamine
    1 interaction

    Monitor/Modify Tx

    sparsentan + phenoxybenzamine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • phentolamine
  • Filspari (sparsentan)
    +
    phentolamine
    1 interaction

    Monitor/Modify Tx

    sparsentan + phentolamine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • pindolol
  • Filspari (sparsentan)
    +
    pindolol
    1 interaction

    Monitor/Modify Tx

    sparsentan + pindolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • piroxicam
  • Filspari (sparsentan)
    +
    piroxicam
    1 interaction

    Monitor/Modify Tx

    sparsentan + piroxicam

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • pitavastatin
  • Filspari (sparsentan)
    +
    pitavastatin
    1 interaction

    Monitor/Modify Tx

    sparsentan + pitavastatin

    monitor CK, myopathy sx: combo may incr. pitavastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport possibly inhibited)

  • plazomicin
  • Filspari (sparsentan)
    +
    plazomicin
    1 interaction

    Monitor/Modify Tx

    sparsentan + plazomicin

    monitor plazomicin levels, renal fxn, ototoxicity: combo may incr. plazomicin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • polyethylene glycol
  • Filspari (sparsentan)
    +
    polyethylene glycol
    1 interaction

    Monitor/Modify Tx

    sparsentan + polyethylene glycol

    monitor renal fxn, especially if polyethylene glycol bowel prep use: combo may incr. risk of nephrotoxicity (additive effects)

  • polyethylene glycol/electrolytes
  • Filspari (sparsentan)
    +
    polyethylene glycol/ electrolytes
    1 interaction

    Monitor/Modify Tx

    sparsentan + polyethylene glycol/ electrolytes

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • potassium acid phosphate
  • Filspari (sparsentan)
    +
    potassium acid phosphate
    1 interaction

    Monitor/Modify Tx

    sparsentan + potassium acid phosphate

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • potassium bicarbonate
  • Filspari (sparsentan)
    +
    potassium bicarbonate
    1 interaction

    Monitor/Modify Tx

    sparsentan + potassium bicarbonate

    monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

  • potassium citrate
  • Filspari (sparsentan)
    +
    potassium citrate
    1 interaction

    Monitor/Modify Tx

    sparsentan + potassium citrate

    monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

  • potassium iodide
  • Filspari (sparsentan)
    +
    potassium iodide
    1 interaction

    Monitor/Modify Tx

    sparsentan + potassium iodide

    monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

  • pramipexole
  • Filspari (sparsentan)
    +
    pramipexole
    1 interaction

    Monitor/Modify Tx

    sparsentan + pramipexole

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • pravastatin
  • Filspari (sparsentan)
    +
    pravastatin
    1 interaction

    Monitor/Modify Tx

    sparsentan + pravastatin

    monitor CK, myopathy sx: combo may incr. pravastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport possibly inhibited)

  • prazosin
  • Filspari (sparsentan)
    +
    prazosin
    1 interaction

    Monitor/Modify Tx

    sparsentan + prazosin

    monitor BP, especially during prazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • procarbazine
  • Filspari (sparsentan)
    +
    procarbazine
    1 interaction

    Monitor/Modify Tx

    sparsentan + procarbazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • prochlorperazine
  • Filspari (sparsentan)
    +
    prochlorperazine
    1 interaction

    Monitor/Modify Tx

    sparsentan + prochlorperazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • promethazine
  • Filspari (sparsentan)
    +
    promethazine
    1 interaction

    Monitor/Modify Tx

    sparsentan + promethazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • propafenone
  • Filspari (sparsentan)
    +
    propafenone
    1 interaction

    Monitor/Modify Tx

    sparsentan + propafenone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • propofol
  • Filspari (sparsentan)
    +
    propofol
    1 interaction

    Monitor/Modify Tx

    sparsentan + propofol

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • propranolol
  • Filspari (sparsentan)
    +
    propranolol
    1 interaction

    Monitor/Modify Tx

    sparsentan + propranolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • protriptyline
  • Filspari (sparsentan)
    +
    protriptyline
    1 interaction

    Monitor/Modify Tx

    sparsentan + protriptyline

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • quetiapine
  • Filspari (sparsentan)
    +
    quetiapine
    1 interaction

    Monitor/Modify Tx

    sparsentan + quetiapine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • quinidine (antiarrhythmic)
  • Filspari (sparsentan)
    +
    quinidine (antiarrhythmic)
    1 interaction

    Monitor/Modify Tx

    sparsentan + quinidine (antiarrhythmic)

    monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport possibly inhibited)

  • ramucirumab
  • Filspari (sparsentan)
    +
    ramucirumab
    1 interaction

    Monitor/Modify Tx

    sparsentan + ramucirumab

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • ranolazine
  • Filspari (sparsentan)
    +
    ranolazine
    1 interaction

    Monitor/Modify Tx

    sparsentan + ranolazine

    monitor ECG: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport possibly inhibited)

  • rasagiline
  • Filspari (sparsentan)
    +
    rasagiline
    1 interaction

    Monitor/Modify Tx

    sparsentan + rasagiline

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • remifentanil
  • Filspari (sparsentan)
    +
    remifentanil
    1 interaction

    Monitor/Modify Tx

    sparsentan + remifentanil

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • remimazolam
  • Filspari (sparsentan)
    +
    remimazolam
    1 interaction

    Monitor/Modify Tx

    sparsentan + remimazolam

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • Rho(D) immune globulin
  • Filspari (sparsentan)
    +
    Rho(D) immune globulin
    1 interaction

    Monitor/Modify Tx

    sparsentan + Rho(D) immune globulin

    monitor renal fxn; use lowest Rho(D) immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • rilzabrutinib
  • Filspari (sparsentan)
    +
    rilzabrutinib
    1 interaction

    Monitor/Modify Tx

    sparsentan + rilzabrutinib

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • riociguat
  • Filspari (sparsentan)
    +
    riociguat
    1 interaction

    Monitor/Modify Tx

    sparsentan + riociguat

    monitor BP; consider decr. riociguat start dose to 0.5 mg PO tid: combo may incr. riociguat levels, risk of severe hypotension (including orthostasis, syncope), other adverse effects (BCRP-mediated transport possibly inhibited, additive effects)

  • risperidone
  • Filspari (sparsentan)
    +
    risperidone
    1 interaction

    Monitor/Modify Tx

    sparsentan + risperidone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • rituximab
  • Filspari (sparsentan)
    +
    rituximab
    1 interaction

    Monitor/Modify Tx

    sparsentan + rituximab

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • ropeginterferon alfa-2b
  • Filspari (sparsentan)
    +
    ropeginterferon alfa-2b
    1 interaction

    Monitor/Modify Tx

    sparsentan + ropeginterferon alfa-2b

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • ropinirole
  • Filspari (sparsentan)
    +
    ropinirole
    1 interaction

    Monitor/Modify Tx

    sparsentan + ropinirole

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • ropivacaine
  • Filspari (sparsentan)
    +
    ropivacaine
    1 interaction

    Monitor/Modify Tx

    sparsentan + ropivacaine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • rosuvastatin
  • Filspari (sparsentan)
    +
    rosuvastatin
    1 interaction

    Monitor/Modify Tx

    sparsentan + rosuvastatin

    monitor CK, myopathy sx: combo may incr. rosuvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport possibly inhibited)

  • rotigotine transdermal
  • Filspari (sparsentan)
    +
    rotigotine transdermal
    1 interaction

    Monitor/Modify Tx

    sparsentan + rotigotine transdermal

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • sacubitril
  • Filspari (sparsentan)
    +
    sacubitril
    1 interaction

    Monitor/Modify Tx

    sparsentan + sacubitril

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • safinamide
  • Filspari (sparsentan)
    +
    safinamide
    1 interaction

    Monitor/Modify Tx

    sparsentan + safinamide

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • salsalate
  • Filspari (sparsentan)
    +
    salsalate
    1 interaction

    Monitor/Modify Tx

    sparsentan + salsalate

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • selegiline
  • Filspari (sparsentan)
    +
    selegiline
    1 interaction

    Monitor/Modify Tx

    sparsentan + selegiline

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • selegiline transdermal
  • Filspari (sparsentan)
    +
    selegiline transdermal
    1 interaction

    Monitor/Modify Tx

    sparsentan + selegiline transdermal

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • sevoflurane
  • Filspari (sparsentan)
    +
    sevoflurane
    1 interaction

    Monitor/Modify Tx

    sparsentan + sevoflurane

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • sildenafil
  • Filspari (sparsentan)
    +
    sildenafil
    1 interaction

    Monitor/Modify Tx

    sparsentan + sildenafil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • silodosin
  • Filspari (sparsentan)
    +
    silodosin
    1 interaction

    Monitor/Modify Tx

    sparsentan + silodosin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • simvastatin
  • Filspari (sparsentan)
    +
    simvastatin
    1 interaction

    Monitor/Modify Tx

    sparsentan + simvastatin

    monitor CK, myopathy sx: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport possibly inhibited)

  • sirolimus
  • Filspari (sparsentan)
    +
    sirolimus
    1 interaction

    Monitor/Modify Tx

    sparsentan + sirolimus

    monitor sirolimus levels, renal fxn: combo may incr. sirolimus levels, risk of serious infection, nephrotoxicity, other adverse effects (P-gp-mediated transport possibly inhibited, additive effects)

  • sitagliptin
  • Filspari (sparsentan)
    +
    sitagliptin
    1 interaction

    Monitor/Modify Tx

    sparsentan + sitagliptin

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • sodium bicarbonate
  • Filspari (sparsentan)
    +
    sodium bicarbonate
    1 interaction

    Monitor/Modify Tx

    sparsentan + sodium bicarbonate

    separate admin. w/ oral sodium bicarbonate by at least 2h: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • sodium citrate
  • Filspari (sparsentan)
    +
    sodium citrate
    1 interaction

    Monitor/Modify Tx

    sparsentan + sodium citrate

    separate admin. by at least 2h: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • sodium ferric gluconate complex
  • Filspari (sparsentan)
    +
    sodium ferric gluconate complex
    1 interaction

    Monitor/Modify Tx

    sparsentan + sodium ferric gluconate complex

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • sodium zirconium cyclosilicate
  • Filspari (sparsentan)
    +
    sodium zirconium cyclosilicate
    1 interaction

    Monitor/Modify Tx

    sparsentan + sodium zirconium cyclosilicate

    separate admin. by at least 2h: combo may decr. sparsentan levels, efficacy (absorption decreased at higher gastric pH)

  • sotagliflozin
  • Filspari (sparsentan)
    +
    sotagliflozin
    1 interaction

    Monitor/Modify Tx

    sparsentan + sotagliflozin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • sotalol
  • Filspari (sparsentan)
    +
    sotalol
    1 interaction

    Monitor/Modify Tx

    sparsentan + sotalol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • spironolactone
  • Filspari (sparsentan)
    +
    spironolactone
    1 interaction

    Monitor/Modify Tx

    sparsentan + spironolactone

    monitor BP, potassium, renal fxn: combo may incr. risk of severe hyperkalemia, nephrotoxicity, hypotension, including orthostasis, syncope (additive effects)

  • succinylcholine
  • Filspari (sparsentan)
    +
    succinylcholine
    1 interaction

    Monitor/Modify Tx

    sparsentan + succinylcholine

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • sufentanil
  • Filspari (sparsentan)
    +
    sufentanil
    1 interaction

    Monitor/Modify Tx

    sparsentan + sufentanil

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • sulfate bowel prep
  • Filspari (sparsentan)
    +
    sulfate bowel prep
    1 interaction

    Monitor/Modify Tx

    sparsentan + sulfate bowel prep

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • sulindac
  • Filspari (sparsentan)
    +
    sulindac
    1 interaction

    Monitor/Modify Tx

    sparsentan + sulindac

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • sunitinib
  • Filspari (sparsentan)
    +
    sunitinib
    1 interaction

    Monitor/Modify Tx

    sparsentan + sunitinib

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • tadalafil
  • Filspari (sparsentan)
    +
    tadalafil
    1 interaction

    Monitor/Modify Tx

    sparsentan + tadalafil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • tagraxofusp
  • Filspari (sparsentan)
    +
    tagraxofusp
    1 interaction

    Monitor/Modify Tx

    sparsentan + tagraxofusp

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • talazoparib
  • Filspari (sparsentan)
    +
    talazoparib
    1 interaction

    Monitor/Modify Tx

    sparsentan + talazoparib

    monitor CBC: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (P-gp-mediated transport possibly inhibited, BCRP-mediated transport possibly inhibited)

  • tamsulosin
  • Filspari (sparsentan)
    +
    tamsulosin
    1 interaction

    Monitor/Modify Tx

    sparsentan + tamsulosin

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • tapentadol
  • Filspari (sparsentan)
    +
    tapentadol
    1 interaction

    Monitor/Modify Tx

    sparsentan + tapentadol

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • taurine
  • Filspari (sparsentan)
    +
    taurine
    1 interaction

    Monitor/Modify Tx

    sparsentan + taurine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • telavancin
  • Filspari (sparsentan)
    +
    telavancin
    1 interaction

    Monitor/Modify Tx

    sparsentan + telavancin

    monitor ECG, renal fxn: combo may incr. telavancin levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (additive effects)

  • temsirolimus
  • Filspari (sparsentan)
    +
    temsirolimus
    1 interaction

    Monitor/Modify Tx

    sparsentan + temsirolimus

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • tenofovir alafenamide
  • Filspari (sparsentan)
    +
    tenofovir alafenamide
    1 interaction

    Monitor/Modify Tx

    sparsentan + tenofovir alafenamide

    monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport possibly inhibited, gut BCRP-mediated transport possibly inhibited, additive effects)

  • terazosin
  • Filspari (sparsentan)
    +
    terazosin
    1 interaction

    Monitor/Modify Tx

    sparsentan + terazosin

    monitor BP, especially during terazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • thalidomide
  • Filspari (sparsentan)
    +
    thalidomide
    1 interaction

    Monitor/Modify Tx

    sparsentan + thalidomide

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • thioridazine
  • Filspari (sparsentan)
    +
    thioridazine
    1 interaction

    Monitor/Modify Tx

    sparsentan + thioridazine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • thiothixene
  • Filspari (sparsentan)
    +
    thiothixene
    1 interaction

    Monitor/Modify Tx

    sparsentan + thiothixene

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • timolol
  • Filspari (sparsentan)
    +
    timolol
    1 interaction

    Monitor/Modify Tx

    sparsentan + timolol

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • timolol ophthalmic
  • Filspari (sparsentan)
    +
    timolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    sparsentan + timolol ophthalmic

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • tiopronin
  • Filspari (sparsentan)
    +
    tiopronin
    1 interaction

    Monitor/Modify Tx

    sparsentan + tiopronin

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • tivozanib
  • Filspari (sparsentan)
    +
    tivozanib
    1 interaction

    Monitor/Modify Tx

    sparsentan + tivozanib

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • tizanidine
  • Filspari (sparsentan)
    +
    tizanidine
    1 interaction

    Monitor/Modify Tx

    sparsentan + tizanidine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • tolcapone
  • Filspari (sparsentan)
    +
    tolcapone
    1 interaction

    Monitor/Modify Tx

    sparsentan + tolcapone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • tolmetin
  • Filspari (sparsentan)
    +
    tolmetin
    1 interaction

    Monitor/Modify Tx

    sparsentan + tolmetin

    monitor renal fxn, potassium: combo may incr. risk of nephrotoxicity, hyperkalemia (additive effects)

  • tolvaptan
  • Filspari (sparsentan)
    +
    tolvaptan
    1 interaction

    Monitor/Modify Tx

    sparsentan + tolvaptan

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • torsemide
  • Filspari (sparsentan)
    +
    torsemide
    1 interaction

    Monitor/Modify Tx

    sparsentan + torsemide

    monitor BP, renal fxn: combo may incr. risk of nephrotoxicity, hypotension, including orthostasis, syncope (additive effects)

  • tramadol
  • Filspari (sparsentan)
    +
    tramadol
    1 interaction

    Monitor/Modify Tx

    sparsentan + tramadol

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • tranylcypromine
  • Filspari (sparsentan)
    +
    tranylcypromine
    1 interaction

    Monitor/Modify Tx

    sparsentan + tranylcypromine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • trazodone
  • Filspari (sparsentan)
    +
    trazodone
    1 interaction

    Monitor/Modify Tx

    sparsentan + trazodone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • treprostinil
  • Filspari (sparsentan)
    +
    treprostinil
    1 interaction

    Monitor/Modify Tx

    sparsentan + treprostinil

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • triamterene
  • Filspari (sparsentan)
    +
    triamterene
    1 interaction

    Monitor/Modify Tx

    sparsentan + triamterene

    monitor BP, potassium, renal fxn: combo may incr. risk of severe hyperkalemia, nephrotoxicity, hypotension, including orthostasis, syncope (additive effects)

  • trifluoperazine
  • Filspari (sparsentan)
    +
    trifluoperazine
    1 interaction

    Monitor/Modify Tx

    sparsentan + trifluoperazine

    monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

  • trimethoprim
  • Filspari (sparsentan)
    +
    trimethoprim
    1 interaction

    Monitor/Modify Tx

    sparsentan + trimethoprim

    monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

  • trimipramine
  • Filspari (sparsentan)
    +
    trimipramine
    1 interaction

    Monitor/Modify Tx

    sparsentan + trimipramine

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • ubrogepant
  • Filspari (sparsentan)
    +
    ubrogepant
    1 interaction

    Monitor/Modify Tx

    sparsentan + ubrogepant

    limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of adverse effects (P-gp-mediated transport possibly inhibited, BCRP-mediated transport possibly inhibited)

  • vaccinia immune globulin
  • Filspari (sparsentan)
    +
    vaccinia immune globulin
    1 interaction

    Monitor/Modify Tx

    sparsentan + vaccinia immune globulin

    monitor renal fxn; use lowest vaccinia immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • valacyclovir
  • Filspari (sparsentan)
    +
    valacyclovir
    1 interaction

    Monitor/Modify Tx

    sparsentan + valacyclovir

    monitor renal fxn: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • vancomycin
  • Filspari (sparsentan)
    +
    vancomycin
    1 interaction

    Monitor/Modify Tx

    sparsentan + vancomycin

    VANCOMYCIN IV: monitor renal fxn, vancomycin levels, ototoxicity; VANCOMYCIN PO: consider monitoring renal fxn, vancomycin levels, ototoxicity in pts w/ severe renal impairment, severe intestinal inflammation, or prolonged course >2 g/day: combo may incr. vancomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects; incr. oral vancomycin absorption if inflamed or compromised gut mucosa)

  • vardenafil
  • Filspari (sparsentan)
    +
    vardenafil
    1 interaction

    Monitor/Modify Tx

    sparsentan + vardenafil

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • verapamil
  • Filspari (sparsentan)
    +
    verapamil
    1 interaction

    Monitor/Modify Tx

    sparsentan + verapamil

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects; may decr. verapamil levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

  • voclosporin
  • Filspari (sparsentan)
    +
    voclosporin
    1 interaction

    Monitor/Modify Tx

    sparsentan + voclosporin

    monitor potassium, renal fxn: combo may incr. risk of severe hyperkalemia, nephrotoxicity (additive effects)

  • vosoritide
  • Filspari (sparsentan)
    +
    vosoritide
    1 interaction

    Monitor/Modify Tx

    sparsentan + vosoritide

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • warfarin
  • Filspari (sparsentan)
    +
    warfarin
    1 interaction

    Monitor/Modify Tx

    sparsentan + warfarin

    monitor INR: combo may decr. warfarin levels, efficacy (hepatic metabolism induced)

  • willow bark
  • Filspari (sparsentan)
    +
    willow bark
    1 interaction

    Monitor/Modify Tx

    sparsentan + willow bark

    monitor renal fxn, especially w/ high-dose willow bark: combo may incr. risk of nephrotoxicity (additive effects, willow bark may contain salicylates)

  • yohimbe
  • Filspari (sparsentan)
    +
    yohimbe
    1 interaction

    Monitor/Modify Tx

    sparsentan + yohimbe

    monitor BP, especially w/ high yohimbe doses: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • ziprasidone
  • Filspari (sparsentan)
    +
    ziprasidone
    1 interaction

    Monitor/Modify Tx

    sparsentan + ziprasidone

    monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

  • ziv-aflibercept
  • Filspari (sparsentan)
    +
    ziv-aflibercept
    1 interaction

    Monitor/Modify Tx

    sparsentan + ziv-aflibercept

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

  • zoledronic acid
  • Filspari (sparsentan)
    +
    zoledronic acid
    1 interaction

    Monitor/Modify Tx

    sparsentan + zoledronic acid

    monitor renal fxn: combo may incr. zoledronic acid levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • zonisamide
  • Filspari (sparsentan)
    +
    zonisamide
    1 interaction

    Monitor/Modify Tx

    sparsentan + zonisamide

    monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)

Caution Advised

  • bupropion
  • Filspari (sparsentan)
    +
    bupropion
    1 interaction

    Caution Advised

    sparsentan + bupropion

    caution advised: combo may decr. bupropion and metabolite levels, efficacy (hepatic metabolism induced)

  • carisoprodol
  • Filspari (sparsentan)
    +
    carisoprodol
    1 interaction

    Caution Advised

    sparsentan + carisoprodol

    caution advised: combo may decr. carisoprodol levels, incr. active metabolite meprobamate levels, alter risk of adverse effects and efficacy (hepatic metabolism possibly induced, incr. conversion to active metabolite)

  • darolutamide
  • Filspari (sparsentan)
    +
    darolutamide
    1 interaction

    Caution Advised

    sparsentan + darolutamide

    if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

  • glecaprevir
  • Filspari (sparsentan)
    +
    glecaprevir
    1 interaction

    Caution Advised

    sparsentan + glecaprevir

    caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited, BCRP-mediated transport possibly inhibited)

  • naldemedine
  • Filspari (sparsentan)
    +
    naldemedine
    1 interaction

    Caution Advised

    sparsentan + naldemedine

    caution advised: combo may incr. naldemedine levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

  • nevirapine
  • Filspari (sparsentan)
    +
    nevirapine
    1 interaction

    Caution Advised

    sparsentan + nevirapine

    caution advised: combo may decr. nevirapine levels, efficacy (hepatic metabolism induced)

  • pibrentasvir
  • Filspari (sparsentan)
    +
    pibrentasvir
    1 interaction

    Caution Advised

    sparsentan + pibrentasvir

    caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited, BCRP-mediated transport possibly inhibited)

  • seladelpar
  • Filspari (sparsentan)
    +
    seladelpar
    1 interaction

    Caution Advised

    sparsentan + seladelpar

    caution advised if also combined with OATP1B1 and/or OATP1B3 inhibitor: combo may incr. seladelpar levels, risk of adverse effects (BCRP-mediated transport possibly inhibited)

  • sulfasalazine
  • Filspari (sparsentan)
    +
    sulfasalazine
    1 interaction

    Caution Advised

    sparsentan + sulfasalazine

    caution advised: combo may incr. sulfasalazine levels, risk of adverse effects; may decr. IBD tx efficacy (gut BCRP-mediated transport possibly inhibited)

  • velpatasvir
  • Filspari (sparsentan)
    +
    velpatasvir
    1 interaction

    Caution Advised

    sparsentan + velpatasvir

    caution advised: combo may decr. velpatasvir levels, efficacy (hepatic metabolism induced)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@5af1294a
  • acute kidney injury
  • hypotension
  • hyperkalemia

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@12ffcd3c
  • hyperkalemia
  • hypotension
  • edema, peripheral
  • dizziness
  • anemia
  • acute kidney injury
  • ALT or AST elevated
  • eGFR decr.

Safety/Monitoring .

Monitoring Parameters
AST/ALT, bilirubin before tx start, then q3mo; pregnancy test before tx start; Cr; K

Pregnancy/Lactation .

Pregnancy

Clinical Summary

contraindicated during pregnancy; inadequate human data available; risk of fetal harm, including craniofacial malformations, skeletal abnormalities, decr. fetal wt, and embryo-fetal death based on animal data at 10x MRHD

Individuals of Reproductive Potential

obtain negative pregnancy test before tx start; avoid pregnancy by using effective contraception before tx start, during tx, and x2wk after D/C in patients of childbearing potential

Lactation

Clinical Summary

avoid use while breastfeeding; no human data available to assess risk of infant harm or effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@46379a9c

Metabolism: for sparsentan: liver; CYP450: 3A (primary) substrate

Excretion: for sparsentan: feces 80% (9% unchanged), urine 2% (minimally unchanged); Half-life: 9.6h

Subclass: Endothelin and Angiotensin II Receptor Antagonists

Mechanism of Action
for sparsentan: selectively antagonizes endothelin type A receptor and angiotensin II type 1 receptor

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: Travere Therapeutics, Inc.

com.epocrates.rxweb.beans.DrugOtherInfoBean@68200886

DEA/FDA: Rx

Retail Price

This information is currently not available for this drug.

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information